Embryonic and adult cardiac stem cells - molecular, electrophysical and immunological characteristics for cardiac repair by Genead, Rami
Department of Medicine Huddinge, Division of Cardiology 
Karolinska Institutet, Stockholm, Sweden 
 
EMBRYONIC AND ADULT 
CARDIAC STEM CELLS - 
MOLECULAR, 
ELECTROPHYSIOLOGICAL AND 
IMMUNOLOGICAL 
CHARACTERISTICS FOR 
CARDIAC REPAIR 
Rami Genead 
 
 
Stockholm 2011 
 
 
  
All previously published papers were reproduced with permission from the publisher. 
 
Published by Karolinska Institutet. Printed by Larserics Digital Print AB 
 
© Rami Genead, 2011 
ISBN 978-91-7457-436-4 
 
 
 2 
                                                                                   Embryonic and Adult Cardiac SCs 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                
 
 
                                    “Education consists mainly of what we have unlearned”  
                                                                                                               Mark Twain 
 
 
 
      “The will to win, the desire to succeed, the urge to reach your full potential...  
these are the keys that will unlock the door to personal excellence”  
                                                                                                                  Confucius 
 
 
 
 
 
 
 
 
 
                                                                                        
 
                                                                                       To My Great Family  
   3
 
  
CONTENTS 
1 ABSTRACT....................................................................................................... 6 
2 LIST OF PUBLICATIONS............................................................................... 7 
3 LIST OF ABBREVIATIONS ........................................................................... 8 
4 INTRODUCTION ............................................................................................. 9 
4.1 Magnitude of cardiovascular disease....................................................... 9 
4.2 Cardiac regenerative cell-based therapy.................................................. 9 
4.3 Endogenous regenerative potential of the heart .................................... 11 
4.3.1 Embryonic cardiac stem / progenitor cells ................................ 12 
4.3.2 Adult cardiac stem / progenitor cells......................................... 14 
4.4 Human embryonic stem cells................................................................. 15 
4.4.1 HESCs’ capacity to generate cardiomyocytes .......................... 15 
4.4.2 Immunological aspects of cell-based transplantation ............... 17 
4.4.3 The immunogenicity of HESCs................................................. 19 
4.4.4 Tolerance Induction ................................................................... 19 
5 AIMS ................................................................................................................ 22 
6 MATERIALS AND METHODS .................................................................... 23 
6.1 Animals and ethics ................................................................................. 23 
6.2 Processing of human embryonic material ............................................. 23 
6.3 Animal Surgery and Handling ............................................................... 23 
6.3.1 Anesthesia and Post-Operative Care ......................................... 23 
6.3.2 Induction of myocardial ischemia in the rat model- Paper III.. 23 
6.3.3 Induction of immunologic tolerance of transplanted HESCs ... 24 
6.4 Cardiosphere Culture and Freezing- Paper I ......................................... 24 
6.5 Immunostaining / Detection of transplanted cells ................................. 25 
6.5.1 Immunohistochemistry / Immunocytochemistry ...................... 25 
6.5.2 Western blot / Immunoblotting.................................................. 27 
6.5.3 Transmission electron microscopy (TEM) - Paper I................. 27 
6.5.4 Fluorescence in situ hybridization (FISH) - Paper IV .............. 27 
6.6 Electrophysiological characterization- Paper I...................................... 28 
6.6.1 Multi-electrode array (MEA)..................................................... 28 
6.7 Immunological characterization- Paper IV............................................ 28 
6.7.1 Mixed leukocyte reaction (MLR).............................................. 28 
6.7.2 Histological evaluation of the immune response ...................... 29 
6.8 Real-Time Polymerase Chain Reaction (RT-PCR) - Paper III............. 29 
6.9 Statistical analysis .................................................................................. 30 
7 RESULTS......................................................................................................... 32 
7.1 Paper I ..................................................................................................... 32 
7.2 Paper II.................................................................................................... 34 
7.3 Paper III .................................................................................................. 38 
7.4 Paper IV.................................................................................................. 40 
8 GENERAL DISCUSSION .............................................................................. 42 
8.1 The journey of Isl1 cells along the life span .......................................... 42 
8.1.1 Spatial and time-dependent analysis of Isl1+ cells ................... 42 
8.1.2 The differentiating and proliferative capacity of Isl1+ cells..... 45 
8.2 CPCs turnover in response to stress...................................................... 48 
 4 
                                                                                   Embryonic and Adult Cardiac SCs 
   5
8.3 Is it possible to induce immune tolerance towards HESCs?...........50 
9 CONCLUSIONS........................................................................................53 
10 FUTURE PERSPECTIVES.......................................................................54 
11 ACKNOWLEDGMENTS .........................................................................55 
12 REFERENCES...........................................................................................58 
13 ORIGINAL PAPERS I-IV.........................................................................68 
 
 
 
 
 
 
 
 
 
 
 
 
  
1 ABSTRACT 
Background: The concept of myocardial regeneration by means of stimulating the 
endogenous regenerative potential in situ is an attractive approach. This offers distinct 
advantages to stem cell implantation where the problems with engraftment and immune 
rejection are avoided. Resident cardiac progenitors (CPCs) have emerged as promising 
optimal candidates for cardiac repair. The overall aim of this thesis was to identify and 
characterize the Isl1+ cells as promising CPCs; from the molecular, 
electrophysiological as well as immunological aspects in which human embryonic stem 
cells (HESCs) were used as a template for our planned transplantation studies.  
 
Methods and Results: In papers I-III, based on both protein and transcriptional level 
analyses, we have identified the Isl1+ CPCs throughout the entire life span, both from 
the embryonic human heart and from the embryonic to the adult rat heart. Early in 
development the Isl1+ cells were mainly in the para-cardiac regions (pharyngeal 
foregut endoderm, splanchnic mesoderm, areas suggested to be the second heart field), 
while later in development they become predominantly localized in the following 
cardiac subdomains: outflow tract, inflow region of the right atrium and the upper part 
of right ventricle. Some of the Isl1+ cells were differentiating, while others were 
undifferentiated. However, only a minority of the Isl1+ cells was proliferating in 
contrary to the majority of the ventricular embryonic cardiomyocytes. After birth, 
immature Isl1+ cells were still present in the OFT where they resided until adulthood. 
Their distribution within the heart matched the defined embryonic distributions. 
Spontaneously beating in vitro cardiospheres were obtained from the embryonic human 
heart, exhibiting rate-response to electrical and pharmacological stimuli. To explore 
how cardiac regeneration and cell turnover adapted to disease, different forms of stress; 
physiological and pathological were studied for their effects on the CPC markers c-Kit 
and Isl1. Among the different stress modalities, ischemia-reperfusion (IR) injury was 
the strongest stimulus for activation of markers suggesting endogenous cardiomyocyte 
regeneration, correlating to the endogenous up-regulation of IGF-1 and HGF. There 
was a spatial mismatch on one hand of c-Kit and on the other hand Isl1 expression. 
In paper IV, HESCs were used to test if the triple costimulation blockade regimen in a 
mouse model could induce a long-term immune tolerance to in-vivo transplanted 
HESCs to the testis and the heart. Costimulation blockade induced tolerance to 
undifferentiated HESCs in the immune-privileged environment of the testis and 
induced regulatory T-cells to HESCs when transplanted into the myocardium of 
immunocompetent mice. A booster dose of costimulation blockade induced HESC 
engraftment in one out of five immunocompetent mice.  
 
Conclusions: The human embryonic heart is a potential source for the Isl1+ CPCs. 
These Isl1+ CPCs are present during the whole life span from the embryonic period 
until adulthood. They seem to have the capacity to differentiate into a cardiac specific-
lineage. IR injury among other stresses was the strongest stimulus with both global and 
focal cardiomyocyte progenitor cell markers up-regulations in the adult heart. Short-
term treatment with the costimulation blockade is sufficiently robust to induce long-
term tolerance to transplanted HESCs in an immune-privileged environment and to 
induce regulatory T-cells when transplanted to the myocardium. 
 
 
Key words: human resident cardiac progenitor, Isl1, c-Kit, Nkx2.5, IGF-1, HGF, 
ischemia-reperfusion injury, HESCs, costimulation blockade and tolerance. 
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4 INTRODUCTION 
4.1 MAGNITUDE OF CARDIOVASCULAR DISEASE 
Cardiovascular disease (CVD) is a disabling growing epidemic that causes premature 
death and decreased quality of life. CVD remains the leading cause of morbidity and 
mortality in the Western World, causing the death of an estimated 17.1 million people 
each year. By 2030, almost 23.6 million people are expected to die from heart disease 
and heart failure, according to the World Health Organization (Taylor et al., 2008). 
Among the most common causes of CVD is ischemic heart disease (IHD) which if 
untreated properly may lead to the development of heart failure. With heart failure 
development series of gross and microscopic structural and cellular changes known as 
cardiac remodelling take place; among these changes the loss of the contractile 
cardiomyocytes is the dominant feature (Frangogiannis, 2008; Dobaczewski et al., 
2010).  
The human heart is comprised of about 2-6 billion cardiomyocytes (Olivetti et al., 
1995), and other recent reports revealed that the heart of young adults from 17 to 30 
years of age were determined to have an average of 6.0 and 2.2 billion cardiomyocytes 
in the left and right ventricular myocardium, respectively (Anversa and Olivetti, 2002). 
Cardiomyocyte deficiency underlies most of the causes of heart failure. A 25- 30% 
infarct size could induce heart failure and the myocyte deficit in this infarction-induced 
heart failure corresponds to about one billion cardiomyocytes (Murry et al., 2006; 
Robey et al., 2008). A similar pattern was observed in other cardiac disorders such as 
hypertension as well as aging, in which a considerable loss of the cardiomyocyte mass 
occurred over years (Whelan et al., 2010; Olivetti et al., 1991). 
Current approaches in the management of IHD and its implications; both medical and 
interventional, can only delay progression of the disease and the only standard therapy 
that addresses the fundamental problem of cardiomyocyte loss is heart transplantation. 
However, there are several problems and side-effects related to this procedure like 
donor availability, logistics, and transplant rejection.  
The crucial issue is restoration and regeneration of the damaged myocardium, which 
remains a tremendous challenge, despite the major advances in this field. Cardiac 
regenerative stem cell-based therapy has emerged as a growing and promising approach 
for therapeutic myocardial regeneration and improvement of cardiac functions.  
 
   
4.2 CARDIAC REGENERATIVE CELL-BASED THERAPY 
Over the last decade, cardiac cell-based regenerative medicine has gone through 
exciting developments, starting with an initial phase of enthusiasm followed by a 
transient stage of suspicion whereas today regenerative medicine is going through 
major important steps to become clinically implemented.  
One of these important steps is that we are continuously revising the findings from 
animal and human studies as regards which cell will be the optimal cell type for cardiac 
regeneration. By definition, the ideal cell type employed for cardiomyoplasty should be 
able to counteract the remodelling process as a part of heart failure development, which 
means that they should be able to generate new contractile cardiomyocytes, smooth 
muscle and endothelial cells to form new vasculature, and contractile myocardium. The 
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first cell type to be tested in clinical phase I trials was the skeletal myoblasts (Menasché 
et al., 2001).  
In animal studies the myoblasts have proven advantageous since it was possible to use 
autologous cells. These could be expanded to millions of cells without changing their 
phenotype and after implantation they formed myotubes and improved left ventricular 
function (Hagège et al., 2003; Leobon et al., 2003). The  first clinical phase I trials have 
demonstrated the feasibility of implanting autologous skeletal myoblasts concomitantly 
with coronary artery bypass grafting (CABG) and the patients improved 
symptomatically but developed problems with ventricular arrhythmias necessitating  
implantation of implantable cardioverter-defibrillators (ICD) (Hagege et al., 2006; 
Siminiak et al., 2004). The positive results on heart failure symptoms stimulated 
Menasché and co-workers to perform a multicenter, placebo controlled, randomized 
trial, the MAGIC trial which enrolled 120 patients. The results after 6 months were 
quite depressing since no significant improvement in cardiac function was observed. 
Instead they reported increased early postoperative arrhythmic events after myoblasts 
transplantation (Menasche et al., 2008). This trial ended the utilization of myoblast as a 
potential source for regenerating the heart. 
 
Another set of cells that fuelled the field of cardiac regeneration were the bone marrow- 
derived somatic cells like the hematopoietic and mesenchymal stem cells. Quaini and 
co-workers in 2002 were first to demonstrate that in sex-mismatched cardiac 
transplants, a donor female heart transplanted into a male host contained Y-
chromosomes in the cardiac cells, indicating their extra-cardiac origin (Quaini et al., 
2002). Several positive animal studies have initiated enthusiasm to use autologous 
hematopoietic stem cells for regenerating the myocardium (Balsam et al., 2004; 
Jackson et al., 2001). One of these earlier studies was the study by Orlic and co-
workers in 2001 (Orlic et al., 2001). In this study, bone marrow-derived Lin-/ c-Kit+ 
cells were shown to regenerate 68% of the infarcted area in a mouse model. These 
findings have been hard to be repeated by other groups (Balsam et al., 2004; Nygren et 
al., 2004; Terada et al., 2002; Murry et al., 2004) and according to the results by 
Nygren and other groups the effect exerted by these stem cells might be due to for 
example cell-fusion instead of transdifferentiation (Nygren et al., 2004; Alvarez-
Dolado et al., 2003). Nonetheless, clinical trials using different subfractions of 
hematopoietic stem cells in patients with ischemic heart failure and chronic heart 
failure have been initiated.  
Several clinical trials have used autologous cell populations. The first, randomized, 
controlled study was the BOOST trial (Wollert et al., 2004; Meyer et al., 2009), where 
bone-marrow mononuclear cells were delivered via intracoronary route 5 days after 
percutaneous coronary intervention (PCI). This study showed short but not long-term 
improvement of cardiac function. In contrast, the Repair-AMI trial (Schachinger et al., 
2006; Assmus et al., 2010) reported a modest improvement of the left ventricular 
function at both 4 and 12 months follow-up. The results so far have not been so 
convincing and we still do not know if these cells actually develop into cardiomyocytes 
in humans, the mechanism through which these cells work, and if they have therapeutic 
paracrine effects.  
 
The mesenchymal stem cells (MSCs) are different from the hematopoietic stem cells. 
These cells appear to be able to regenerate damaged myocardium both by exerting 
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paracrine effects, i.e. homing new cardiomyocytes and endothelial cells to the site of 
injury with induced angiogenesis (Mirotsou et al., 2007), but also by demonstrating a 
capacity to differentiate into cells similar to cardiomyocytes  (Toma et al., 2002; Behfar 
et al., 2010). These cells contain contractile elements, but they do not contract 
spontaneously and they do not give rise to mature cardiomyocytes, not even after 
implantation to ischemic myocardium (Behfar et al., 2010). By directed cell expansion 
mesenchymal stem cells have been directed to a cardiomyocyte fate. These 
cardiopoietic mesenchymal stem cells have been tested in a clinical phase II trial and 
reported to induce physiological as well as clinical therapeutic efficacy in patients with 
chronic ischemic heart failure (Terzic et al, www.clincaltrials.gov) (Bartunek et al., 
2011). 
 
This means that none of the tested stem cells so far have been demonstrated to give rise 
to mature cardiomyocytes that can replace the damaged myocardium after ischemic 
injury. For this reason it is logical to continue the search for stem / progenitor cells 
found in the embryonic and adult heart, in order to use them as templates for the 
generation of stem cells for cardiomyoplasty. Another approach might be to promote 
existing cardiac stem cells and thus prevent progression to heart failure. 
 
 
4.3 ENDOGENOUS REGENERATIVE POTENTIAL OF THE HEART 
Several reports suggest that every adult mammalian tissue harbors a stem / progenitor 
cell population that could maintain or regenerate the host tissue in response to injury: 
bronchoalveolar stem cells (Kim et al., 2005), oval stem cells in liver (Gennero et al., 
2010), and the quiescent satellite cell population that resides in a niche within the adult 
skeletal muscle, which becomes activated in response to severe injury (Meeson et al., 
2007). 
In the case of the heart, the regenerative potential seems to differ between different 
species. In metazoans such as newt and zebrafish, complex processes of cardiac 
regeneration have been revealed in response to injury (Bettencourt-Dias et al., 2003; 
Kikuchi et al., 2010; Jopling et al., 2010). 
In mammals, for decades cardiomyocytes were seen as post-mitotic, lacking the 
capacity of self-repair after the neonatal period, eventually leading to heart failure if the 
myocardium was subjected to damage (Soonpaa and Field, 1997; Fernandez et al., 
2001).  
This old paradigm has been questioned over the last years. Even the adult heart seems 
to have an inborn regenerative capacity throughout life, probably from extra-cardiac 
sources where progenitors migrate and repopulate damaged myocardium, but this 
process occurs at very low rates  (Laflamme et al., 2002). The adult heart is not a 
terminally differentiated organ but maintains limited regenerative capacity throughout 
life. 
This notion is based on several studies in human and mouse using labeling strategies 
and genetic models. In humans, Bergmann and coworkers examined the cardiomyocyte 
turnover by measuring the radiocarbon (carbon 14) incorporation into the DNA 
(Bergmann et al., 2009). Nuclear bomb testing during the cold war increased the 
atmosphere concentrations of carbon 14, which subsequently was incorporated into the 
DNA of any living organism. By measuring the concentration of carbon 14 in different 
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organs, it was possible to get a quantification of cellular turnover and kinetics. This 
cellular dating technique and mathematical modeling support the notion that the adult 
human heart is capable of cellular turnover (representing cardiomyocyte renewal) at the 
rate of 1% per year at the age of 25 years, declining to about to 0.4% per year by the 
age of 75 years. This translates to that about 50% of the cardiomyocytes of an 
individual are being replaced during a life-time. 
In another study, the rate of cardiac DNA synthesis was studied in post-mortem hearts 
from cancer patients treated with the thymidine analogue iododeoxyuridine, which 
incorporates into nascent DNA (Kajstura et al., 2010). Data revealed remarkably high 
rates of DNA labeling in cardiomyocytes, ranging from 2.5 to 46%.  
Hsieh and co-workers used an inducible cardiomyocyte-specific transgenic fate-
mapping (MerCreMer) strategy in the mouse, which allowed for the measurement of 
cardiomyocyte turnover in the adult mouse heart (Hsieh et al., 2007). These genetic 
studies were further supported by bromodeoxyuridine incorporation studies which 
supported the hypothesis that cardiomyocyte renewal occurred after myocardial injury  
 
In summary, these studies support the notion that the postnatal mammalian heart has 
the capacity for cardiomyocyte renewal and turnover capabilities, which can be further 
increased after injury. However these elegant studies, do not explore the underlying 
mechanisms for this cardiomyocyte turnover, i.e. whether cardiac stem /progenitors 
were involved or not. In order to understand the endogenous regenerative capacity of 
the heart, it is mandatory to first go briefly through the concept of the embryonic heart 
development.  
 
 
4.3.1 Embryonic cardiac stem / progenitor cells 
4.3.1.1 Brief insight into the heart development 
To date, most of the studies trying to explore the cellular and molecular mechanisms 
underlying the cardiac development have been based on murine models. 
The heart is the first organ to develop in the embryo. The formation of the four-
chambered heart from the pre-cardiac mesoderm into a well-developed pumping organ 
is a complex process. This process requires a diversity of cell types with specialized 
functions: cardiac muscle, endothelial, vascular, conduction cells, smooth muscle cells 
and interstitial fibroblasts (Vincent and Buckingham, 2010).  
Recently, several studies have revealed increasing evidence that the diverse cell types 
in the heart are largely generated from multipotent cardiac progenitors arising from the 
early heart fields (Buckingham et al., 2005; Abu-Issa et al., 2004; Chien et al., 2008; 
Meilhac et al., 2004).  
Two heart fields (HF), from which the embryonic heart develops, have been identified. 
These HF are defined as distinct embryonic regions in which cells that have myocardial 
potential are located (Abu-Issa et al., 2004). The earliest population of cardiac 
progenitors that comprises the first heart field (FHF) originates in the anterior 
splanchnic mesoderm giving rise to the cardiac crescent and subsequently the early 
heart tube and the left ventricle. Progenitors from the second heart field (SHF) that is 
derived from the pharyngeal mesoderm, anterior and medial to cells of the FHF, give 
rise to most of the cells of the right ventricle and the outflow tract (Abu-Issa et al., 
2004; Buckingham et al., 2005). 
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As development progresses the heart tube forms and then undergoes looping to 
ultimately form the primitive chambers. The heart subsequently receives important 
contributions from two additional sources, the cardiac neural crest and the 
proepicardium. Cardiac neural crest cells contribute to normal development of the 
outflow tract and great vessels as well as important parts of the cardiac autonomic 
nervous system (Epstein and Buck, 2000; Hutson and Kirby, 2007); meanwhile the 
proepicardial cells migrate onto the surface of the heart, giving rise to the epicardium. 
Little data is available as regards the transcriptional and molecular profile of the early 
heart development and most of our understanding is based on studies in animal models. 
To date, the cellular and molecular programming of the SHF cells has been better 
studied than the transcriptional regulation of the FHF cells.  
The cardiac stem / progenitor cells that comprise the majority of the cells of SHF and 
seem to give rise to a major part of the developing heart (Cai et al., 2003), are the Isl1 
progenitors. For this reason Isl1 cells are the main focus in this thesis.  
 
4.3.1.2 Isl1 cardiac progenitors overview 
Initial analysis of Isl1 null mice revealed an essential role of the transcription factor Isl1 
in pancreatic and motor neuron development, and these mice died at embryonic stage 
E9.5 (Pfaff et al., 1996). Further studies revealed that Isl1 was reported as an insulin 
enhancer-binding protein expressed in cell lines of the pancreatic endocrine organ 
(Karlsson et al., 1990) and furthermore essential to control motor neuron differentiation 
during embryogenesis (Tsuchida et al., 1994; Thor et al., 1999). 
Its importance for cardiac formation was discovered in early studies in chick embryos 
that revealed that the LIM–homeodomain transcription factor Isl1 was shown to be a 
marker of the heart field, that is expressed in undifferentiated cells in the cardiogenic 
mesoderm (Yuan and Schoenwolf, 2000). 
Indirect lineage tracing experiments using the Cre-loxP strategy in mice have 
demonstrated that most of the cells of the early second heart field can be traced to 
multipotent heart progenitors that express the LIM-homeodomain transcription factor 
Isl1 (Sun et al., 2007; Moretti et al., 2006). Isl1 is transiently expressed in cardiac 
mesoderm, and although it is not strictly cardiac-specific, its expression has been used 
to identify cardiac progenitor cells. In addition in vivo cell lineage tracing in mouse 
embryos have confirmed that Isl1+ progenitors contribute to more than two-thirds of 
the cells in the embryonic heart including most of the cells of the conduction system, 
proximal coronary artery tree, atria, right ventricle, and outflow tract (Qyang et al., 
2007; Cai et al., 2003). Cai and co-workers, have revealed that hearts of Isl1 null mice 
display severe cardiac defects, including complete absence of the outflow tract and 
right ventricle and partial loss of the atria (Cai et al., 2003). 
 
A problem though is that most of the previous studies were based on indirect lineage 
tracing, retrospective clonal analysis, and transgenic models instead of studying the 
expression of the functional protein in order to identify the nature of these Isl1 cells. 
This means that cells actually expressing the Isl1 protein have not been characterized 
and usually there is a difference between gene transcripts and protein expression. 
Despite the fact that the Isl1+ cells are not fully characterized, they seem to be potent 
cells for regeneration of cardiac tissue. If these Isl1 cells are also present as progenitors 
in the adult heart or they disappear after birth is still unclear.  
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4.3.2 Adult cardiac stem / progenitor cells  
Resident cardiac progenitor cells (CPCs) represent a responsive stem cell reservoir 
within the adult myocardium. These CPCs offer distinct advantages over the other 
circulating adult stem cells, like the bone marrow-derived stem cells. CPCs are 
precommitted to differentiate into cells of the cardiovascular entity, furthermore they 
are autologous and tissue-specific (Beltrami et al., 2003; Gonzales and Pedrazzini, 
2009). 
Adult progenitor cells that reside within the myocardium can be autochthonous, that is, 
leftovers of the embryonic life entrapped in the differentiated tissue, or allochthonous, 
that is, recruited from the bone marrow (or other organs) through the blood stream. 
 
Many research groups have reported on different types of cardiac progenitor cells in 
different species with varying degree of cardiomyogenic potential and these cells 
exhibit stem cell-like properties, being multipotent and self-renewed.  
These cells have been classified according to their properties and their expression of 
surface markers (Table 1), such as c-Kit (Beltrami et al., 2003; Dawn and Bolli, 2005), 
stem cell antigen-1 (Sca-1) (Oh et al., 2003; Matsuura et al., 2004), side population 
(Martin et al., 2004; Pfister et al., 2005), stage-specific embryonic antigen-1 (SSEA-1) 
(Ott et al., 2007), cardiospheres and/or cardiosphere-derived CPCs (Messina et al., 
2004; Smith et al., 2007). Another source of adult CPCs with a great potential for 
regeneration is the epicardium (Cai et al., 2008; Zhou et al., 2008; Smart et al., 2007; 
Smart et al., 2011). 
 
Table 1. Phenotypic characterization of resident cardiac stem / progenitor cells 
CM: cardiomyocyte; SMCs: smooth muscle cells; ECs: endothelial cells; EPDCs: 
epicardium-derived cells; CS/CDCs: cardiosphere / cardiosphere-derived cells. 
 
In addition to the tissue committed monopotent or multipotent resident stem / 
progenitor cells (CPCs), there is growing evidence indicating that adult organs contain 
some other more primitive pluripotent stem cells (PSCs). One recent example is the 
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discovery of pluripotent stem cells known as very small embryonic-like (VSEL) stem 
cells, based on their small size,  in the bone marrow, solid organs, umbilical cord blood 
and peripheral blood of mouse (Kucia et al., 2007; Ratajczak et al., 2008) and humans 
(Wojakowski et al., 2009). VSELs are non-hematopoietic expressing Sca-1+ /Lin− 
/CD45− as well as markers of pluripotency like Oct-4, Nanog, and SSEA-1 (mouse) 
and SSEA-4 (human). They can be differentiated into the three germ layers (Ratajczak 
et al., 2008). Wojakowski and his colleagues reported mobilization of VSELs 
expressing pluripotent markers, early cardiac and endothelial markers, and the 
chemokine receptor CXCR4 in patients with acute myocardial infarction (Wojakowski 
et al., 2009). The VSELs have been identified in the adult human myocardium 
expressing embryonic marker SSEA-4 (Wojakowski et al., 2011).  
 
Although these cells hold a promising regenerative potential for cardiac repair, several 
challenges still remain to be clarified like their origin, the degree of overlap of the 
distinct sub-populations, their ability to retain their cardiogenic potential in disease or 
with aging. To which extent can their in vitro proliferative and differentiation potential 
be translated into a definitive in vivo beneficial effect on the injured tissue?  
 
 
4.4 HUMAN EMBRYONIC STEM CELLS 
The inborn regenerative capacity of the myocardium will not be enough to replace large 
areas of damaged myocardium. The endogenous cardiac progenitors may be suitable 
templates for the desired phenotype of the implanted cells. In order to generate 
sufficient quantities of these cells more immature cell may be needed, which can be 
expanded and differentiated in vitro. Human embryonic stem cells (HESCs) are 
prototypal stem cells, because they unambiguously fulfill all requirements of stem cells: 
self renewal, clonality and multipotency (Thomson et al., 1998).   
 
Human embryonic stem cells (HESCs), which are isolated from the inner cell mass of 
the human blastocyst, can be propagated in vitro indefinitely, while still retaining their 
capacity to differentiate into almost all cell types. Their pluripotency has been proved 
by injecting undifferentiated HESCs into immunodeficient mice that resulted in 
teratocarcinoma including all three germ layers: endoderm, ectoderm, and mesoderm 
(Thomson et al., 1998; Reubinoff et al., 2000). Furthermore a variety of studies have 
described in vitro spontaneous and directed differentiation of HESCs to different 
lineages: neurons and glia (Carpenter et al., 2001; Reubinoff et al., 2001; Johnson et al., 
2007), endothelial cells (Levenberg et al., 2002), hematopoietic precursors (Kaufman et 
al., 2001), trophoblast (Xu et al., 2002), hepatocyte-like cells (Rambhatla et al., 2003; 
Chen and Zeng, 2011), and cardiomyocytes (Xu et al., 2002; Kehat et al., 2001). 
 
 
4.4.1 HESCs’ capacity to generate cardiomyocytes   
HESCs can probably be used in the future for cardiac repair, but then HESCs need to 
be differentiated into cardiomyocyte lineage. One approach to initiate differentiation of 
HESCs is to remove them from the fibroblast feeder layer and culture them in 
suspension. Then HESCs will aggregate into three-dimensional structures termed 
embryoid bodies (EBs). The aggregation process itself triggers cell differentiation. It is 
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thought that the EBs consist of derivatives of all three germ layers, and some of them 
start to contract spontaneously in culture (Itskovitz-Eldor et al., 2000; Doevendans et 
al., 2000). 
Despite that these EBs harbor a panel of myocardial phenotypes based on 
transcriptional and protein analysis (Passier and Mummery, 2003; Gepstein, 2002), 
there will be a risk of teratoma formation upon in vivo transplantation (Kolossov et al., 
2006). The conversion of undifferentiated ESCs into cardiomyocytes is still an 
inefficient process (Passier and Mummery, 2005; Laflamme et al., 2005; Lev et al., 
2005; Kehat et al., 2001).  
In order to produce more pure populations of cardiomyocytes with an adult molecular 
and electrophysiological phenotype (Sartiani et al., 2007), and thereby reducing the risk 
of teratoma formation, several strategies have been tried such as using ESCs in a 
monolayer culture, and co-culturing with either mature cardiomyocytes or visceral 
endodermal cells (END2) (Mummery et al., 2003) or using stimulating agents like 5-
azacytidine, retinoic and ascorbic acid or growth factors like TGFß, FGF, IGF and 
PDGF families (Gepstein, 2002; Heng et al., 2004). Another approach is genetic 
manipulation involving cardiac specific promoters (Klug et al., 1996) or non-genetic 
approach using either mitochondrial fluorescent dyes (Hattori et al., 2010) or surface 
marker proteins such as cellular prion protein (Hidaka et al., 2010). This protein serves 
as an effective surface marker for isolating nascent cardiomyocytes as well as 
cardiomyogenic progenitors.  
 
Induced pluripotent stem (iPS) cells expressing all the cardinal features of pluripotent 
stem cells have been generated by over-expressing four defined transcription factors 
(Oct3/4, Sox2, c-myc and Klf4) (Takahashi and Yamanaka, 2006) or with (Oct3/4, 
Sox2, NANOG and LIN28) (Yu et al., 2007) in several cell types, including fibroblasts.  
Being autologous and patient specific, the use of iPS cells may overcome issues related 
to immunocompatability and bypass the ethical considerations associated with 
generation of ESCs. However, still controversial issues are holding back the clinical 
application of iPS. One of these issues is the heterogeneity in terms of plasticity and 
epigenetic labeling (Kim et al., 2010). Another issue is that the use of iPS poses the 
same risk of teratoma formation as ESCs, related to the impurity of the generated cell 
population. The human iPS cells can differentiate into various cell types, including 
cardiomyocytes (see review (Nelson et al., 2010)). However, the efficiency of 
cardiomyocyte differentiation is still not optimal. Applying the same strategies used for 
ESCs will improve the efficiency of cardiomyocyte differentiation before going into the 
clinic.  
Even if these characteristics of the HESCs or iPS make them attractive sources of cells 
for cardiac repair there are other obstacles besides teratoma formation that must be 
considered before getting into the clinic. One vital issue is that HESCs are mainly 
derived from in vitro fertilization which means they are of allogeneic origin and will be 
rejected when transplanted into recipients. The immunogenicity of iPS cells has so far 
not been fully studied. In order to avoid this problem the immunogenicity of these 
pluripotent stem cells needs to be further characterized. In this thesis focus is only on 
HESCs. The immunological aspects of cell-based therapy will be highlighted through 
the next section, before further addressing the immunogenicity of HESCs. 
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4.4.2 Immunological aspects of cell-based transplantation 
A major obstacle to bring allogeneic regenerative cell-based therapy into clinic will be 
avoiding the immune response towards the transplanted cells. This will subsequently 
require the long-term use of immunosuppressive regimens with its major drawbacks 
and side effects like cancer, renal insufficiency, osteoporosis, and hypertension. 
 
The immune response can either be innate, adaptive or both. Rejection to transplants 
occurs due to differences in a multitude of antigens, which can be divided into three 
major groups: human ABO blood-group antigens, human leucocyte antigen/major 
histocompatibility complex (HLA/MHC), and the minor histocompatibility complex 
(mHC) (Bradley et al., 2002). 
The ABO antigens consist of structurally highly polymorphic carbohydrate residues 
bound to cell-surface glycolipids and are expressed on almost every cell in the body 
(Clausen and Hakomori, 1989; Ito and Hirota, 1992). Transplantation of vascularised 
organs between ABO incompatible individuals will cause hyperacute rejection, 
mediated by preformed antibodies directed towards the ABO antigens, which activate 
the complement cascade (Paul and Baldwin, 1987; Cooper, 1990). 
Another set of antigens are the HLA antigens, which are responsible for robust 
immunological rejection. They can be divided into HLA/MHC class I (HLA-A, -B, -C) 
and HLA/MHC class II (HLA-DR, -DQ and –DP) (Bradley et al., 2002). Most human 
cells express HLA class I molecules while the expression of HLA class II is restricted 
to antigen-presenting cells (APCs) such as dendritic cells (DCs), B-lymphocytes and 
macrophages (Viret and Janeway, 1999).  
The mHC antigens are cell-derived peptides presented on the cell surface by MHC 
molecules. Snell and co-workers were the first to identify these antigens, on the MHC-
identical donors (Snell, 1964). The graft rejection was slower than for MHC disparate 
mice and therefore these antigens were designated mHC. HESC express mHC and, 
although they are not as immunogenic as MHC and ABO antigens, they can 
nonetheless induce immune rejection (Simpson et al., 2001). 
The immunological mechanisms that cause rejection of a cellular transplant can be 
divided into direct (Figure 1a) and indirect (Figure 1b) T-cell allorecognition pathways 
(Caballero et al., 2006). Under normal conditions, a T-cell receptor (TCR) recognizes a 
self-MHC molecule plus a foreign peptide and this leads to T-cell activation. 
In direct recognition, the TCR recognizes the complex of peptide bound by an 
allogeneic MHC molecule and mistakes it for self-MHC with foreign peptide. In other 
words, an allogeneic MHC molecule with a bound peptide can mimic a particular 
foreign peptide, subsequently also inducing T-cell activation. The direct immune 
response will only be possible if a tissue that is transplanted contains donor APCs or if 
the transplanted cells can function as an APC. A prerequisite for functioning as an APC 
is the expression of MHC class II and of co-stimulatory molecules (Rogers and 
Lechler, 2001). After transplantation, the APCs from the donor tissue migrate to the 
regional lymph nodes in which they encounter and stimulate T-cells. The proliferation 
and differentiation of T-cells into activated T-cells require signals from both the TCR 
and co-stimulatory molecules (Figure 2a).  
The B7 molecules are the classical co-stimulatory molecules expressed on the surface 
of DCs. These ligands bind to CD28 on the surface of T-cells and provide the second 
signal, which is a necessity for activating T-cells. Stimulation of naive T-cells by the 
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TCR without concomitant co-stimulation leads to a state of unresponsiveness called 
anergy (Frasca et al., 1998; Powell and Zheng, 2006). This is a state in which a T-cell is 
not only unresponsive on first encounter, but also remains so upon re-exposure. Some 
of these anergic T-cells develop into regulatory T-cells. These regulatory T-cells have 
the ability to inhibit the activation of new generations of naive T-cells with an affinity 
for the same antigens. In this manner, the immune system is capable of “learning and 
remembering”. Previously activated effector and memory T-cells are less dependent on 
co-stimulation to get activated on second exposure than naive cells. Memory T-cells are 
responsible for the enhanced and accelerated immune response seen upon re-exposure 
to an antigen. The mechanism of memory T-cell generation and survival is a major 
field of investigation and difficulties in tolerance induction in these cells could well be 
the major obstacle to clinical tolerance induction (Kaech et al., 2002).   
In the indirect T-cell allorecognition pathway, foreign peptides and allogeneic MHC 
molecules from the graft are processed and presented by a recipient APC. Processed 
MHC molecules will be recognized by T-cells like other conventional foreign protein 
antigens (Caballero et al., 2006). Indirect presentation results in allorecognition by 
CD4+ T-cells (helper T- cells). The alloantigens are acquired by the host APCs through 
the endosomal vesicular pathway (phagocytosis) and are presented by MHC class II 
molecules. Some antigens of phagocytosed graft material also enter the class I MHC 
pathway of antigen presentation and are recognized by CD8+ T-cells (cytotoxic T-
cells) in a process called cross-presentation. Because MHC molecules are the most 
polymorphic proteins in the genome, each allogeneic MHC molecule may give rise to 
multiple epitopes, each recognized by different T-cells (Fairchild, 1998). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Antigen presentation.  
a. Direct antigen presentation. Intact donor class-I and –II MHC molecules present on the 
surface of donor APC, which emigrate to the nearest lymph node, are recognized directly by 
T-cell receptor (TCR) on the surface of the recipient CD8+ and CD4+ T-cells, respectively. 
These T-cells interpret the donor MHC/peptide complex on the APCs as self-MHC with a 
foreign peptide, which induces T-cell activation and subsequently acute rejection.  
b. Indirect antigen presentation. After implantation, donor antigen shed from the graft are 
internalized, partially processed by recipient APCs and presented as peptides to recipient T-
cells. This will subsequently initiate T-cell activation.   
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4.4.3 The immunogenicity of HESCs  
Whether HESCs are immune-privileged or not is another issue that must be addressed. 
It is not clear if HESCs and their differentiated progeny express ABO blood-group 
antigens but for clinical use this should be screened to avoid ABO incompatibility or 
using HESCs lines selected for the universal donor phenotype (blood group O). 
What is clear is that HESCs express low levels of HLA class I, which is up-regulated 
by IFN-γ stimulation or after differentiation into embryoid bodies or after teratoma 
formation (Grinnemo et al., 2006; Drukker et al., 2002; Li et al., 2004). HLA class II 
molecules, however, are not expressed under these circumstances. The expression of 
co-stimulatory molecules (B7.1, B7.2 and CD40) has also been demonstrated to be low 
or absent on undifferentiated HESCs (Grinnemo et al., 2006; Li et al., 2004). This 
implies that the HESCs lack the two important prerequisites to function as professional 
APCs, namely high levels of HLA class II and co-stimulatory molecules. 
 
To test the immune response evoked in a xenogeneic setting, Drukker and co-workers 
(2006) transplanted HESCs under the kidney capsule of various immunodeficient mice 
strains. Normal teratoma growth was only seen in the T-cell-deficient mice suggesting 
that xenograft rejection of HESCs was a T-cell-mediated immune process. 
To confirm this outcome in an allogeneic setting, a trimeric mouse model was created 
in which the bone marrow was reconstituted with human peripheral blood mononuclear 
cells (human T, B and NK cells) (Drukker et al., 2006). Transplantation of human skin 
or a B cell lymphoma graft caused immune rejection in contrast to HESCs, which 
developed into teratoma.  
In parallel Li and co-workers (2004) showed through in vitro studies using the mixed 
leukocyte reaction (MLR) that HESCs failed to induce proliferation of human 
peripheral blood mononuclear cells. This lack of allogeneic immune response was also 
seen when T-cell-enriched peripheral blood lymphocytes were used. 
Based on these findings, Drukker and co-workers (2006) and Li and co-workers (2004) 
have previously suggested that HESCs are immune-privileged. 
On the other hand, Grinnemo and co-workers have showed that injection of HESCs 
into the myocardium of immunocompetent C57BL/6 mice induced an immune 
rejection which peaked day 5 to 7 (Grinnemo et al., 2006). In a xenogeneic MLR, 
HESCs induced a similar immune response as human fibroblasts when co-cultured with 
mice CD4+ T-cells. Furthermore, lymphocytes isolated from mice previously 
transplanted with HESCs showed increased reactivity upon re-exposure to HESCs, 
indicating that immunological memory had been induced. In an allogeneic MLR, again 
HESCs and human fibroblasts induce a similar immune response when co-cultured 
with purified human CD4+ T-cells and DCs from the same donor. These HESCs 
induce a similar level of proliferation as human fibroblasts, without any sign of 
inhibiting proliferation. According to these data, HESCs are immunologically inert and 
do not inhibit immune responses.  
 
 
4.4.4 Tolerance Induction 
A hallmark of a normally functioning immune system is that a response is only directed 
towards foreign antigens. The avoidance of destruction of self-antigens is referred to as 
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self-tolerance. In order to induce tolerance to a transplanted cell, tissue or organ, we 
need to take both the innate and adaptive arm of immunity in account.  
 
Strategies in transplantation across the immunological barrier 
By reducing the alloantigen differences between host and recipient, transplantation of 
HESCs with a low risk of rejection might be possible. One possible solution would be 
the creation of special stem-cell banks, with cells having different HLA and ABO 
profiles that could be matched to the potential recipient. Another alternative might be to 
use somatic cell nuclear transfer (SCNT) (Wakayama et al., 2001; Wang et al., 2005) to 
create HESCs with antigen expression similar to that of the recipient. Another option 
might be to induce tolerance by co-stimulation blockade. 
Immune tolerance is a state in which non-reactivity to an antigen is maintained in a 
host. In a healthy individual, this state is maintained in all the tissues of the body at a 
number of different checkpoints.  
The most crucial step is the clonal elimination of T-cells with a strong affinity for self-
antigens during the process of negative selection in the thymus. Some self-reactive T-
cells might escape to peripheral immune tissues, where peripheral tolerance 
mechanisms control these potentially self-reactive T-cells. T-cell anergy refers to a 
functional state in which the T-cell becomes hyporesponsive following self-antigen 
encounter in the absence of optimal costimulation by APCs. T-cells chronically 
exposed to a self-antigen can also undergo apoptosis or develop into regulatory T-cells 
(CD4+CD25+Foxp3+), which actively suppress the activation and expansion of self-
reactive T-cells. 
In view of the adaptive and dynamic nature of the immune system, it should be possible 
to manipulate this system in order to induce tolerance. The blockade of costimulatory 
molecules that are necessary for optimal T-cell activation is an attractive strategy to 
induce tolerance to foreign antigens such as alloantigens after organ or cell 
transplantation. 
 
Costimulation blockade has successfully been tested in rodents. The strategy that has 
attracted the greatest attention targets the co-stimulatory molecules CD40L expressed 
on activated T-cells and the B7 molecules expressed on DCs under inflammatory 
circumstances. These co-stimulatory molecules are expressed at the time of 
transplantation and in conjunction with the new antigen. This offers a temporal window 
in which tolerisation specific to donor antigen can be induced. Tolerisation is achieved 
by blocking CD40L with anti-CD40L and the B7 molecules with CTLA4Ig (a fusion 
protein of a high affinity receptor for B7 and the Fc component of human IgG (Figure 
2b). The costimulation blockade is administered only during the first week after 
transplantation. The targeting of these pathways has lead to long-term acceptance of 
vascularised allogeneic and xenogeneic rat cardiac transplants in mice (Larsen et al., 
1996; Elwood et al., 1998). 
 
Depending on the type of tissue to be transplanted and the strain of mouse used as 
recipient, the outcome of tolerance induction with anti-CD40L/CTLA4Ig has been 
variable. This is attributed to the presence of CD8+ T-cells, which are resistant to 
double co-stimulation blockade (Trambley et al., 1999; Corbascio et al., 2002). By also 
targeting LFA-1, an important adhesion and co-stimulatory molecule for CD8+ T-cells, 
CD40L-independent immune activation and cytotoxicity can be inhibited. The addition 
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of anti-LFA-1 treatment to anti-CD40L/CTLA4Ig therapy has been shown to improve 
graft quality and function synergistically in discordant dopaminergic porcine xenografts 
transplanted into the brain of mice (Larsson et al., 2003). This therapy has also been 
shown to induce the permanent acceptance of porcine islet grafts transplanted into wild 
type diabetic mice (Kumagai-Braesch et al., 2007). 
 
If this strategy is also applicable on undifferentiated HESCs is still unclear and should 
be explored. 
 
 
Figure 2. T-cell activation and peripheral tolerance induction 
a. T-cell activation. The initial step in activation of naive T-cells is the binding of the 
T-cell receptor to a specific MHC complex on the membrane of an APC. CD40L binds 
to CD40 on the APC, enhancing the B7 expression on the APC and reinforcing the 
CD28 costimulation in a positive feedback loop. 
b. Costimulation blockade and peripheral tolerance. This is achieved by treatment 
of transplant recipient with anti-CD40L which targets the CD40L expressed on 
activated T-cells and CTLA4Ig, which binds to the B7 (B7.1 and B7.2) molecule 
expressed on dendritic cells under inflammatory circumstances. This interaction 
delivers an inhibitory signal which means that the activated T-cell becomes anergic, 
upon a second exposure to the same antigen.  
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
5 AIMS 
 
The overall aims of this thesis were to explore the potential role of Isl1 progenitor cells 
for cardiac regeneration and to explore if immunologic tolerance induction can be used 
to get allogeneic stem cells into clinic. 
 
The specific aims are listed according to the publications 
 
I- To identify the nature of the Isl1 cardiac progenitor cells in the early first 
trimester human embryonic heart and to characterize the Isl1 cells in regard to 
their proliferation and differentiation capacity in vivo and in vitro. To 
immunohistochemically and electro-physiologically characterize the beating 
cardioshperes derived from the embryonic hearts.  
 
 
II- To longitudinally characterize the distribution of cells actively expressing the 
cardiac progenitor transcription factor Isl1 during the embryonic life, the 
postnatal period, and adulthood in a rat model. To evaluate their proliferative 
and differentiating capacity in vivo. 
 
 
III- To explore how stress can boost the endogenous cardiac regenerative potential, 
through the up-regulation of cardiac progenitor cell markers.  
 
 
IV- To study the immunogenicity and tumorigencity of HESCs as a model for 
future differentiation into cardiac progenitor cells for cardiac repair. To study 
the ability of the costimulation blockade to induce long-term tolerance of the 
transplanted HESCs. To study the difference in engraftment between the testis 
and the myocardium. 
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6 MATERIALS AND METHODS 
6.1 ANIMALS AND ETHICS 
Time-mated and normal adult Sprague-Dawley female rats (Charles River, Germany) 
were used in papers II and III. Male C57BL/6 mice (B and K Universal AB, Sweden) 
and male SCID/Beige (C.B.-17/GbmsTac-SCID-bgDFN7; M and B, Taconic, 
Denmark) were used in paper IV. 
All the procedures were approved by the Animal Care Committee of Karolinska 
University Hospital, Stockholm, Sweden and conform to the Guide for the Care and 
Use of Laboratory Animals published by the US National Institutes of Health [NIH 
Publication No. 85-23, revised 1996]. 
 
 
6.2 PROCESSING OF HUMAN EMBRYONIC MATERIAL 
In paper I, to collect human embryonic tissue, individual permission was obtained 
using a standard informed consent procedure and prior approval by the regional ethical 
committee. The investigation conforms to the principles outlined in the Declaration of 
Helsinki 
In paper IV, human embryonic stem cells (HESC line HS401) were derived and 
cultured at the Fertility Unit, Department of Gynecology, Karolinska University 
Hospital following the approval by the regional ethical committee. 
 
 
6.3 ANIMAL SURGERY AND HANDLING 
6.3.1 Anesthesia and Post-Operative Care 
In papers III and IV, both mice and rats were anaesthetized with intraperitoneal and 
subcutaneous injection of Midazolam (Dormicum, 5mg/kg) (Algol Pharma AB, 
Germany), Medetomidin hydrochloride (Domitor vet, 0.1 mg/kg) (Orion Corp., Espoo, 
Finland), Fentanyl (0.3 mg/kg) (B.Braun Medical AG, Seesatz, Switzerland), 
respectively. Mice were tracheomatized while rats were endotracheally intubated. The 
ventilation was maintained using a ventilator (model CWC600AP and 7025 Rodent 
ventilator, respectively, UGO BASILE S.R.L, Italy). The anesthesia was reversed by an 
intramuscular injection of Flumazenil (Lanexat, 0.1 mg/kg) (Hameln Pharma, 
Germany) and Tipamezol hydrochloride (Antisedan vet 5 mg/kg) (Orion Corp., Espoo, 
Finland). Postoperative analgesia was maintained by administrating Buprenorphin 
hydrochloride (Temgesic, 0.004 mg/kg/ twice per day for 3 days) (Schering-Plough 
Corp., Belgium). Doses were adjusted according to the weight of the animals. 
 
6.3.2 Induction of myocardial ischemia in the rat model- Paper III 
During general anesthesia a left thoracotomy was performed. In the myocardial 
infarction group the left anterior descending artery (LAD) was permanently ligated and 
induction of infarction was confirmed by color change and dyskinesia of the antero-
lateral wall of the left ventricle. In the ischemia-reperfusion groups with or without 
growth factors, the LAD was temporarily ligated during five minutes followed by either 
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an intramyocardial injection of rrIGF-1(8μg) and rhHGF (2μg) dissolved in 10% rat 
serum in PBS or corresponding volume of only 10% rat serum, respectively. 
 
6.3.3 Induction of immunologic tolerance of transplanted HESCs 
Immuno-deficient SCID and immuno-competent C57BL/6 mice were chosen for 
analysis. The HESCs (200 000 cells) were injected either under the capsule of the right 
testis, an immunoprivileged organ (Nasr et al., 2005) or into the healthy myocardium 
(Figure 3). The mice were randomized to receive either costimulation blockade or 
isotype control reagents. The active costimulation blocking reagents used were anti-
LFA-1 (clone M17/5.2), anti-CD40L (clone MR1), CTLA4 Ig, and their respective 
isotype control antibodies: rat IgG2b (clone 9A2), hamster IgG1 and human IgG1 
(Bioexpress, West Lebanon, NH, USA).  
 
 
 
 
 
 
 
 
 
 
 
Figure 3. An intubated C57BL/6 mouse with the heart exposed through a left open 
thoracotomy. HESCs were injected into the myocardium of the left ventricular wall. 
 
 
6.4 CARDIOSPHERE CULTURE AND FREEZING- PAPER I 
The rationale for using the human embryonic cardiosphere model was based on the 
notion that stem cells or cells with stem cell function will only retain their pluripotency 
within an appropriate environment, as suggested by the "niche" hypothesis (Nilsson and 
Simmons, 2004). This model has been studied in several cell types like neural cells 
developed into neurospheres (Galli et al., 2003), some tumor cell lines (LIM) (Bates et 
al., 2000), endothelial cells (Korff and Augustin, 1998) and fetal chicken 
cardiomyocytes (Armstrong et al., 2000). We aimed to test the possibility to reproduce 
the same model in our human embryonic heart material.    
 
Human abortion material (gestational weeks 5 to 10) was transported directly from the 
operating room to the dissection room where the heart was the first organ to be 
identified to reduce the time of ischemia. Gestational age was determined by 
examination of the fetus for morphological landmarks (England, 1990). Time between 
abortion and culture preparation was 0.5–1 h.   
For tissue culture, the cardiac material was first mechanically and then enzymatically 
digested repeatedly in collagenase solution (Collagenase type 2, CLS-2 Worthington 
160 U/mL) until all pieces were completely dissociated. The obtained cells were 
washed by centrifugation and resuspended in knock-out Dulbecco's modified Eagle's 
medium (knock-out DMEM; Invitrogen, UK), nonessential amino acids (GTF, 
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Sweden), Primocin 100 μg/mL medium (Amaxa Inc., USA), 0.1 mmol/L β-
mercaptoethanol (Invitrogen), glutamine 2 mM (Invitrogen), and insulin-transferrin-
selenium supplement (Invitrogen). The cells were seeded directly onto plastic tissue 
plates (Techno Plastic Products AG, Switzerland) and cultured under serum-free 
conditions, in order to prohibit fibroblast growth, thus favoring cardiosphere growth. 
Freezing of the cultured cardiospheres was performed by detaching the cardiospheres 
and resuspending them in freezing medium [0.5 mL 20% knock-out serum replacement 
medium (Invitrogen) and 10% dimethyl sulfoxide (Sigma-Aldrich, USA) in knockout 
DMEM (Invitrogen). The cardiospheres were frozen gradually (−1 °C per minute) 
down to−70 °C and stored at−180 °C. When the frozen cells were recultured, they were 
quickly thawed to 37 °C, washed, and recultured on plastic plates. 
 
 
6.5 IMMUNOSTAINING / DETECTION OF TRANSPLANTED CELLS 
Immunostaining is a general term that applies to any use of an antibody-based method 
to detect a specific functional protein in a sample. This method was fundamentally 
applied to all our studies.  
 
6.5.1 Immunohistochemistry / Immunocytochemistry  
The information concerning all the used primary and secondary antibodies like 
dilutions; clone, company, etc. were described in details in the original papers.  
 
In general, the used material was either paraffin-embedded or cryopreserved and sliced 
into 2.5-to 5-μm-thick sections. The paraffin-embedded sections were deparraffinized 
and frozen sections or cytospinned cells were fixed in 4% formaldehyde or ice-cold 
methanol, blocked with serum and incubated with the primary antibodies. The sections 
or cells were incubated with different fluorescence-labeled secondary antibodies 
(AlexaFluor 488 or 568 and TRITC). The stained cells were embedded in diamidino-2-
phenylindole (DAPI) mounting medium and analyzed by fluorescence microscopy. 
Enzymatic staining using horseradish peroxidase was applied in paper II, to achieve 
better overview of the cardiac and para-cardiac regions. This enzymatic reaction refers 
to a subclass of immunohistochemical procedures in which the antibodies were 
visualized via a peroxidase-catalyzed reaction. In brief, we used diaminobenzidine 
(DAB) as a color developer. Sections were counterstained with hematoxylin, mounted 
in a mounting medium and analyzed using bright field light microscopy. To achieve a 
proper antigen retrieval, the sections were boiled in 0.01 M citric buffer (pH 6.0), 
followed by 10 min incubation in 3% H2O2 to block endogenous peroxidase activity.  
 
Various material and immunohistochemical analyses were used in the different papers: 
in paper I, the human embryonic hearts (5-10 weeks) and cultured cardiospheres; in 
paper II, whole rat embryos, which were sliced in a transverse plane from head to tail, 
together with early postnatal SD rat hearts (days 1–2) and hearts from adult SD rat; in 
paper III, adult SD rat hearts and in paper IV, the hearts and testes from SCID/ Beige 
and C57BL/6 mice. 
In papers I, II and III, the hearts were mechanically minced into small pieces, treated 
with collagenase type II solution (CLS-2; Worthington Biochemical Corporation, 
Lakewood, NJ) to receive single cell suspensions for subsequent cytospin.  
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In papers I and II, the used material was analyzed for the expression of Isl1 as a marker 
for cardiomyocyte progenitor cells, Nkx2.5 as a marker to detect early differentiation 
into cardiomyocytes, Ki67 and histone H3 phosphorylation as markers for active 
cellular proliferation, and finally mature cardiomyocyte (troponin-T, TnT), and smooth 
muscle differentiation markers (α-smooth muscle actin, α-SMA). 
In paper II, two different Isl1 antibodies were used, both goat anti-human Isl1 and 
mouse anti-rat supernatant Isl1  
The goat anti-human Isl1 was used for immuno-fluorescence staining to be able to 
perform co-staining with differentiation and proliferation markers to avoid cross-
reactivity with species of the same origin, while mouse anti-rat supernatant Isl1 was 
used for the immuno-peroxidase staining in paraffin-embedded sections because they 
give a better overview picture of the distribution of Isl1+ cells in the para-cardiac and 
cardiac regions. Both these primary antibodies were tested to stain the same rat Isl1+ 
cells thereby minimizing the risk of misinterpretation (Figure 4). 
 
 
Figure 4. Fluorescent imaging showing the two different Isl1 antibodies used in paper 
II and their co-localization in the same cells which minimize the risk of 
misinterpretation. 
 
In paper I, as positive controls, we used human fetal spinal cord (Isl1), human fetal 
heart (Nkx2.5), adult human atrial appendage (troponin T), and human fetal liver 
(Ki67) and as negative controls adult human spleen. 
In paper II, the following positive controls were used: Isl1 (embryonic rat brain and 
spinal cord); TnT and α-SMA (fetal rat heart); Ki67 (fetal rat liver and intestine). For 
negative controls, the primary antibody was omitted and staining was performed with 
the secondary antibody on the same or the adjacent sections of interest. 
In paper III, we used cytospin preparations of the adult rat hearts and stained for mast 
cells by using Toluidine blue staining. 
Finally, in paper IV, freeze-sectioned hearts and testes were evaluated for the site of 
injection of HESCs via hematoxylin and eosin staining. In case of teratoma formation, 
these sections were further evaluated searching for the structures representing the three 
germ layers. The HESCs and their differentiated progeny were traced using 
fluorescence in situ hybridization technique (FISH) (described under 6.5.4 section). 
The sections with surviving HESC-derived cells in the hearts were further stained for 
the cardiomyocyte markers α-actinin and desmin, together with the marker for 
undifferentiated HESCs, TRA 1–60. As positive controls for the antibodies towards 
desmin and α-actinin we used sectioned human embryonic hearts. 
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6.5.2 Western blot / Immunoblotting 
The Western blot (WB) analysis was used in paper III to be able to quantify the protein 
expressions of the target markers (Isl1, c-Kit and Nkx2.5) in comparison to the 
expression of the internal house-keeping control (GAPDH). WB is based on the 
principle that proteins are generally separated by size during the gel electrophoresis 
step and after blotting the studied proteins could be identified through comparison to 
known molecular weight markers.  
In paper III, WB was used instead of immunohistochemistry (IHC) for two reasons: 
first, by using WB a more accurate quantitative estimation of the target markers (Isl1, 
c-Kit, Nkx2.5) among the different studied groups is obtained; second, interpretative 
difficulties related to background staining when using IHC on cytospin slides of adult 
rat hearts are avoided. 
 
6.5.3 Transmission electron microscopy (TEM) - Paper I 
TEM makes it possible to study tissues and cells at significantly higher resolution than 
with light microscope. This method was used in paper I where we wanted to 
characterize the beating cardiospheres at a sub-cellular level. Briefly, the spontaneously 
beating  cardiospheres were collected with a micropipette and immediately fixed in 2%  
glutaraldehyde and 0.5% paraformaldehyde in 0.1 M sodium cacodylate buffer 
(caco)/0.1 M sucrose/3 mM CaCl2 (pH 7.4) at room temperature for 30 min followed 
by 24 h at 4 °C. The specimens were rinsed in 0.15 M caco containing 3 mM CaCl2 
(pH 7.4) and postfixed by incubation for 2 h at 4 °C in 2% osmium tetroxide in 0.07 M 
caco containing 1.5 mM CaCl2. The specimens were then dehydrated in an ascending 
series of ethanol followed by acetone and embedded in LX-112 epoxy resin (Ladd, 
Burlington, VT, USA). Semithin sections (0.5 μm) were placed on glass slides, stained 
with toluidine blue, and examined under a light microscope. Ultrathin sections (40–50 
nm) were cut and contrasted with uranyl acetate followed by lead citrate and examined 
using a Tecnai 10 (FEI, Eindhoven, Netherlands) transmission electron microscope set 
at 80 kV. 
 
6.5.4 Fluorescence in situ hybridization (FISH) - Paper IV 
In paper IV, the HESCs and their differentiated progeny were traced using fluorescence 
in situ hybridization technique (FISH). This is a cytogenetic technique that is used to 
detect and localize the presence or absence of specific DNA sequences on 
chromosomes. FISH uses fluorescent probes that only bind to those parts of the 
chromosome which show a high degree of sequence homology. 
In our study, the aim was to detect DNA sequences specific for the human genome of 
the transplanted cells that would provide unequivocal genetic evidence for the accurate 
localization and identification of grafted cells in histological sections. These 
fluorescence inmarked DNA-probes that hybridized to the total human DNA of viable 
cells, labeled the whole nucleus. 
In brief, the paraffin-embedded slides were deparraffinized. The samples were fixed 
onto cover slips, followed by denaturation of both fluorescent-labeled oligonucleotide 
probes and target DNA followed by overnight incubation to allow the probe to be 
hybridized with the sample. In the next step, excess probes were washed away, and 
fluorescence microscopy was used to view the location of the hybridized cells i.e. the 
implanted human cells. 
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6.6 ELECTROPHYSIOLOGICAL CHARACTERIZATION- PAPER I 
6.6.1 Multi-electrode array (MEA) 
The multi electrode-array method is well-described in numerous publications (Stett et 
al., 2003; Halbach et al., 2003). This MEA (Multi Channel Systems, Reutlingen, 
Germany) was chosen for an in vitro electrophysiological recording to allow collection 
of data from multiple sites in a non-invasive way in comparison to the patch-clamp 
method. Extracellular recordings were performed to characterize the basal electrical 
activity of the beating cardiospheres. Each MEA had 60 flat, round, substrate-integrated 
titanium nitride electrodes in an 8×8 grid and an integrated reference electrode 
(electrode diameter 30 μm and interelectrode distance 200 μm) (Figure 5). The MEA 
was connected to an amplifier with a heated stage (Multi Channel Systems, Reutlingen, 
Germany). All recordings were carried out at 37 °C with culture medium gassed with 
5% CO2. 
 
 
 
 
 
 
 
 
Figure 5. Microelectrode array heating system and culture dish. 
 
 
Spontaneously beating cardiospheres were selected and planted onto MEA plates pre-
coated with human collagen IV (Sigma-Aldrich) or polyethyleneimine (PEI) + laminin. 
Two days after planting, the cells had attached to the plates, integrating mechanically 
and electrically, and forming large, simultaneously beating clusters covering several 
electrodes. Recordings were carried out within 5 days of planting.  
Recordings were carried out at a sampling frequency of 1 kHz and lasted for 2 minutes. 
The resulting field potentials (FPs) were characterized regarding interbeat interval (IBI) 
and waveform properties such as FPMIN, FPMAX, and FPDUR. Thirty successive FPs 
were averaged to reduce background noise and facilitate manual recognition of FPMAX. 
To study the rate dependency of the action potential duration (APD), one cardiosphere 
cluster was paced with an external electrode in 100-ms steps at intervals between 1000 
and 600 ms. The sensitivity to β-receptor stimulation was studied by adding 36 μM 
isoprenaline in the culture medium to the beating cardiosphere culture. Data were 
acquired and analyzed using MC Rack software (Multi Channel Systems). 
 
 
6.7 IMMUNOLOGICAL CHARACTERIZATION- PAPER IV 
6.7.1 Mixed leukocyte reaction (MLR) 
The in vitro MLR method was performed to show if the in vivo immune reaction upon 
HESCs transplantation could be mimicked. The aim was to show if  regulatory T-cells 
collected from mice treated with costimulation blockade could modulate the immune 
response induced by HESCs and whether this response is specific to HESCs or not.    
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Dendritic cells (DC) were prepared from the bone marrow of syngeneic C57BL/6 mice 
according to the protocol previously described (Grinnemo et al., 2006). Splenocytes 
from naive C57BL/6 mice, C57BL/6 mice from the costimulation blockade-treated and 
the isotype control groups were used for this experiment. The spleens were 
homogenized and the CD4+ T-cells were separated and CD4+CD25+ T-cells from 
C57BL/6 mice of the costimulation blockade and isotype control groups were 
separated. The DC were co-cultured with either irradiated HESCs or human fibroblasts 
(HFib). The MLR was performed exposing naive CD4+ T-cells to syngeneic DC alone 
or syngeneic DC co-cultured with HESCs or HFib. To study if the regulatory T-cells 
from mice treated with costimulation blockade or its isotype control reagents could 
specifically down-modulate the immune response induced by HESCs, the previously 
separated CD4+CD25+ T-cells were added to the wells. Each culture was labeled with 
2µCi [3H] thymidine 20 h prior to harvest. The proliferation of the responders was 
measured at day 6 as counts per minute (cpm) and each experiment was performed in 
triplicate (Figure 6) 
                                                               
Schematic figure 6. Mixed leukocyte reaction (MLR): In brief, naive CD4 T-cells 
were exposed to syngeneic DC alone or DC co-cultured with HESCs or HFib. CD4+ 
CD25+ regulatory T-cells were added to the culture wells. Each well was labeled with 
radioactive reagent (3H) thymidine which allows the measurement of cell proliferation 
as counts per minute (cpm).      
 
 
6.7.2 Histological evaluation of the immune response 
The inflammatory response was evaluated by hematoxylin and eosin staining together 
with immunohistochemical analysis for CD3, CD4 and CD8 (markers of helper and 
cytotoxic T-cells, respectively, CD11b (activated macrophages) and FoxP3 (regulatory 
T-cells). Spleens from C57BL/6 were used as positive controls, whereas hearts from 
SCID/beige mice served as negative controls for the primary antibodies. 
 
 
6.8 REAL-TIME POLYMERASE CHAIN REACTION (RT-PCR) - PAPER III 
The hearts were harvested through a left thoracotomy. The hearts were kept cold on dry 
ice and subsequently divided into the different sub-domains; outflow tract, right 
ventricle, left ventricle and when applicable the area of peri-ischemia and peri-infarct. 
 
 
 
  
 
 
 
 
 
 
 
 
  
All the heart samples were snap-frozen in liquid nitrogen and kept in minus 70oC until 
RNA extraction. Total RNA was extracted from the heart samples according to the 
QuickGene RNA tissue assay (RT-S2, Science Imaging Scandinavia AB, Sweden) 
using the Fuji QuickGene-QG-810/QG-800Mini80 RNA isolation system. The RNA 
concentrations and purities (A260/280) were measured in a NanoDrop 
spectrophotometer® (ND-1000) (Nanodrop technologies, Wilmington, DE, USA). The 
RNA quality was further evaluated by 1 % agarose-gel electrophoresis. 
Two micrograms of total RNA was reverse transcribed by Superscript reverse 
transcriptase (Life Technologies, Stockholm, Sweden) using random hexamer primers 
(Roche Diagnostics GmbH, Mannheim, Germany) in a total volume of 20 μl.  
Real-time PCR was used to measure mRNA expression on a 7500 Fast real-time PCR 
system (Applied Biosystems Inc., Foster City, CA, USA). Primers and probes were 
supplied as a TaqMan® Reagents kit (Applied Biosystems). GAPDH was used as an 
endogenous control to correct for potential variation in cDNA loading.  
All PCR reactions were performed in 96-well MicroAmp Optical plates (Applied 
Biosystems). cDNA was diluted 1:5. Amplification reagents (10 μl) contained 1 μl 
sample for c-Kit and Nkx2.5 and 5μl for Isl1 in TaqMan Universal PCR Mastermix.  
All samples were run in duplicates. Each RT-PCR cycle consisted of: initial activation 
stage at 95oC (10 min), then the denaturation stage at 95oC (15 sec) and the annealing 
stage at 60oC (60 sec) cycled 40 times.  
The comparative ∆Ct method was used to calculate the relative gene expression to 
GAPDH for the genes analyzed (Winer et al., 1999). 
 
 
6.9 STATISTICAL ANALYSIS 
Data were presented as mean ± SD in all papers apart from paper II where values were 
presented as mean ± standard error (SE). 
In papers I and II: Statistical heterogeneity was tested by Student’s unpaired t –test.  
In papers III and IV, Non-parametric (Mann-Whitney U) test was used. 
In paper III: Statistical correlations were analyzed with the Pearson correlation test. 
Statistical heterogeneities of P < 0.05 and P < 0.001 were considered to be statistically 
significant and highly significant, respectively. 
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7 RESULTS 
7.1 PAPER I 
 
Aims 
To identify the nature of the Isl1 cardiac progenitor cells in the early first trimester 
human embryonic heart and to characterize the Isl1 cells in regard to their proliferation 
and differentiation capacity in vivo and in vitro. To immunohistochemically and 
electro-physiologically characterize the beating cardioshperes derived from the 
embryonic hearts.  
 
Results 
In vivo Isl1 progenitor cells distribution and characterization 
In the early first trimester hearts (gestational weeks 5-9) Isl1+ cells were mainly 
clustered in the outflow tract and to a lesser extent in the atria and in the right ventricle. 
Some of the clusters were also expressing the cardiac contraction-related protein 
troponin T. Unexpectedly only few Isl1+ cells were Ki67+ while in the ventricles the 
majority of Isl1− troponin T+ cells were Ki67+ (Figure 7).  
 
In vitro cardiosphere characterization 
Cultures derived from the digested embryonic heart developed into spontaneously 
beating cardiospheres. At harvest, cells in these cardiospheres showed frequent 
expression of troponin T and Nkx2.5, while Isl1 was expressed only in scattered cells. 
Only a minority of the cultured cells expressed Ki67. The cardiospheres could be 
frozen, thawed, and recultured to beating cardiospheres. Electron microscopy revealed 
plenty of gap junctions between the cells in the beating cardiospheres together with 
contractile elements together with mitochondria and glycogen deposits, indicating 
metabolically active cells (Figure 8). 
In the MEA system, autonomous interbeat interval (IBI) and field potential duration 
(FPdur) were determined from the beating cardiosphere clusters (1579 ms, SD = 633, 
range 923-2748 ms and 172 ms, SD = 58, range 110-265 ms respectively). Pacing in 
100-ms steps at intervals between 1000 ms and 600 ms resulted in a rate-dependent 
decrease in FPdur of up to 35% at the highest stimulation frequency. β-adrenergic 
stimulation with isoprenaline shortened the IBI with 54% (P<0.05) and FPdur with 
23% (P<0.05) (Figure 9). 
 
Conclusions  
The early first trimester human embryonic heart expressed clusters of Isl1+ cells; some 
were in the differentiation process, while others were in the undifferentiated progenitor 
form. Unexpectedly, only a minority of the Isl1+ cells, in contrary to the majority of 
ventricular cardiomyocytes, were proliferating. Spontaneously beating cardiospheres 
could be derived from the human embryonic heart and these cardiospheres were 
responsive to both electrical and pharmacological β-adrenergic stimulation. 
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Figure 9
Figure 7. In vivo characterization of a 5.5 
weeks embryonic heart.  
Panel A: H & E staining of a 5.5 week 
embryonic heart delineating the different 
cardiac chambers. 
Panel (B–E): The Isl1+cells were localized 
mainly in the proximal and the distal outflow 
tract. As shown in D and E, some of the 
Isl1+cells in the distal outflow tract were in 
the maturation and differentiation process 
expressing troponin T (red arrow), while 
some were in their undifferentiated form 
(white arrow). 
Panels F and G: The Isl1 and Ki67 
expression in human embryonic heart. Only 
scattered nuclei co-expressed Ki67 and Isl1. 
Panel H: Human embryonic ventricular 
myocardium with co-expression of troponin 
T and Ki67.  
Bars represent 200 μm in (A), 100 μm in (B 
and C), and 50 μm in (D- H). 
Figure 8.
me
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deposits (G
gap junctions (GJ) with the 
surrounding cardiomyocyte. The 
contractile elements were not 
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 Electron microscopy of a 
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eric structures (S), 
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to both electrical (upper right) and pharmacological β-
adrenergic stimulation (bottom) FPdur and IBI data are 
presented as mean ± SD.  * P<0.05. 
  
7.2 PAPER II 
Aims  
To longitudinally characterize the distribution of cells actively expressing the cardiac 
progenitor transcription factor Isl1 in a rat model from the embryonic period to 
adulthood. To further evaluate the in vivo proliferative and differentiating capacity of 
Isl1+ cells. 
 
Results 
Distribution and characterization of Isl1+ cells in the embryonic heart 
from gestational day 11 to 15 
The Isl1 expression in the upper part (outflow tract and atrial compartment) was 2.5 
times higher than in the lower part (ventricular compartment) along the whole 
embryonic lifespan (Figure 11). In early cardiac development gestational day 11 (GD 
11), the Isl1+ progenitors were located in a greater abundance in the para-cardiac 
regions including pharyngeal foregut endoderm and splanchnic mesoderm, areas 
suggested to be the second heart field (SHF). To a lesser extent, Isl1+ cells were 
present within the bulbotruncal region and the truncus arteriosus. During the following 
days until GD 15, the Isl1+ cells were mainly observed in the proximal outflow tract 
and in the inflow area of the right atrium (Figure 10). No Isl1+ cells were detected in 
the left ventricle. Compared to GD 11, more Isl1+ cells seemed to co-express 
cardiomyocyte (TnT) and smooth muscle (α-SMA) markers and a minority of the Isl1+ 
cells was undifferentiated (Figure 12). Unexpectedly, only few undifferentiated Isl1+ 
cells were Ki67+ while a lot of TnT+ cardiomyocytes were proliferating in the 
ventricles (Figure 14). Our data suggests that during embryogenesis, Isl1+ cells migrate 
from extra-cardiac regions into the proximal part of the heart, proliferating and giving 
rise to cardioblasts. Unexpectedly, only a minority of the Isl1+ cells while a majority of 
ventricular cardiomyocytes were proliferating.  
 
Distribution and characterization of Isl1+ cells in the postnatal and adult 
hearts 
After birth, immature Isl1+ cells were still present in the outflow tract where they 
resided until adulthood. We show for the first time the existence of the Isl1+ cell pool 
in the adult hearts, localized within the myocardial layer of the proximal OFT as 
scattered cells, all expressing the cardiomyocyte marker TnT. No undifferentiated Isl1+ 
cells were observed in the adult heart (Figure 13). 
 
Conclusions  
In this systematic longitudinal study based on immunostaining during the embryonic 
morphogenesis of the heart, Isl1+ cells changed their distribution from extra-cardiac 
structures into the proximal part of the heart. Some of these cells were actively 
proliferating and part of the cells was in the process of differentiation and maturation 
co-expressing cardiomyocyte or smooth muscle cell markers. The Isl1+ cell pool 
persisted into adulthood.  
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Figure 10. Isl1+ cell distribution from the early embryonic stage to postnatal life 
showing the dynamic Isl1 expression in both the cardiac and para-cardiac regions.  
The present sections of the heart were sliced in a transverse plane from head to tail as 
shown in the schematic picture, where 1: outflow tract, 2: right ventricle, 3: left 
ventricle, 4: right atrium, 5: left atrium. Isl1+ cells (immunoperoxidase, HRP, brown 
cells). The section from the postnatal heart shows brown cells in the left part of the 
section. Abbreviations: OFT, outflow tract; LV, left ventricle; CA, common atrial 
chamber; SP, splanchnic mesoderm; FVE, foregut ventral endoderm; T, trachea; BT, 
bulbotruncal region; TA, truncus arteriosus. 
 
 
 
 
 
 
 
 
 
 
 
Figure 11. Distribution of Isl1+ cells in the upper and lower compartments of the 
developing heart. 
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Figure 12. Isl1+ cell distribution, cardiomyocyte and smooth muscle differentiation 
in the cardiac and para-cardiac regions in the embryonic period (GD11-GD15). 
Some Isl1+ cells are in the differentiated form expressing either TnT (Isl1+/ TnT+) 
(red arrow) or α-SMA, while other Isl1 cells are in the undifferentiated stage (white 
arrow). Data were shown both in vivo and in cytospin. OFT: outflow tract; CA: 
common atrial chamber; GD: gestational day. 
 
Figure 13. Distribution of undifferentiated Isl1+ cells together with cells proliferating 
and differentiating into cardiomyocytes at postnatal day 2 (upper panel). 
In the adult heart (lower panel), the Isl1+ cells were localized within the myocardial 
layers of the outflow tract, all expressing the mature cardiomyocyte marker TnT 
(orange arrow). 
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Figure 14. Distribution of actively proliferating Isl1+ cells and TnT+ cardiomyocytes 
in the embryonic heart.  
Upper panel revealed that the majority of the embryonic cardiomyocytes (TnT+) 
express both Ki67 and Isl1 meanwhile only few Isl1 express Ki67 in the inflow part 
of right atrium (Inf. RA) (upper left, red arrows). Lower panel using histone H3 to 
confirm the proliferative capacity (M phase), it is evident that only few Isl1+ cells in 
the OFT undergo mitosis (left, white arrows) while the ventricular (V) 
cardiomyocytes have a much higher proliferative capacity (right, white arrows). OFT: 
outflow tract. 
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7.3 PAPER III    
Aims 
To explore how physiological and pathological stress could boost the endogenous 
cardiac regenerative potential, through the up-regulation of cardiac progenitor cell 
markers.  
 
Results 
The effect of ischemia-reperfusion injury, myocardial infarction and 
pregnancy on the expression of Isl1, c-Kit, and Nkx2.5 
While pregnancy and myocardial infarction up-regulated Nkx2.5 and c-Kit (adjusted 
for mast cell activation) (P<0.05), ischemia-reperfusion (IR) injury induced the 
strongest matched up-regulation (P<0.001, R= 0.524) which occurred globally 
throughout the entire heart and not just around the site of injury (Figure 18).  
Isl1 was not up-regulated by pregnancy or myocardial infarction but by ischemia-
reperfusion injury (P<0.05), mainly in the outflow tract but also in the remote areas of 
the left ventricle (LV) and peri-ischemic regions (Figure 17). 
 
Endogenous IGF-1 and HGF are involved in the up-regulation of cardiac 
progenitors 
Endogenous up-regulation of IGF-1 was correlated to both increased c-Kit and Isl1 
expressions (P = 0.003, R = 0.235 and P = 0.005, R= 0.241) (Figure 16). Endogenous 
HGF expression was correlated to increased c-Kit and Nkx2.5 expressions.  
Furthermore the addition of IGF-1 and HGF in the IR group did stimulate their 
endogenous expression in the peri-ischemic region (P<0.05), which was also related to 
focal up-regulation of Isl1 in the OFT and the peri-ischemic region (P<0.05). c-Kit 
expression was not further influenced by the exogenous growth factor administration.  
This indicates that there is a spatial mismatch between on one hand c-Kit and Nkx2.5 
expression and on the other hand Isl1 expression. 
 
Functional protein expression correlates with mRNA pattern  
The mRNA expression patterns of c-Kit, Isl1 and Nkx2.5 were confirmed at the protein 
level at two weeks using Western blot analysis, where the highest protein expression of 
c-Kit, Isl1 and Nkx2.5 was observed in the IR injury groups (Figure 15). 
 
Conclusions 
Ischemia-reperfusion injury was the strongest stimulus for activation of endogenous 
cardiomyocyte regeneration, correlating to the endogenous up-regulation of IGF-1 
and HGF. There was correlation between the up-regulation of both progenitor 
markers Isl1 and c-Kit and the up-regulation of the early cardiomyocyte marker 
Nkx2.5.  
Figure 15. Western Blot analysis revealed the protein 
expression for c-Kit, Isl1 and Nkx2.5 at 2 weeks. 
Functional protein expression correlates with mRNA 
pattern where the highest protein expression was observed 
in the ischemia-reperfusion injury group. 
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R = 0.241, P < 0.005 R = 0.235, P < 0.005 R = 0.524, P < 0.001 
 Figure 16. Scatter plots showing a strong pos
c-Kit expression. Isl1 and c-Kit expressions
endogenous IGF-1 expression. 
 
 
 
 
itive correlation between the Nkx2.5 and 
 were also positively correlated to the 
 
Figure 17. mRNA expression of Isl1 which revealed that ischemia-reperfusion injury 
induced a robust up-regulation compared to permanent myocardial infarction (left 
panel). This pattern of up-regulation was focally observed, primarily localized to the 
outflow tract and the right ventricle. The expression of Isl1 was also stimulated by IGF-
1 and HGF, especially in the outflow tract area (right panel). 
 
Figure 18. mRNA expression of Nkx2.5 and c-Kit at 2 weeks post-intervention in the 
different cardiac sub-domains.  
Ischemia-reperfusion injury induced the strongest matched up-regulation. This up-
regulation occurred globally throughout the entire heart and not just around the site of 
injury. 
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7.4 PAPER IV 
Aims 
To study the immunogenicity and tumorigencity of HESCs as a model for future 
differentiation into cardiac progenitor cells for cardiac repair. To study the ability of the 
costimulation blockade to induce long-term tolerance of the transplanted HESCs. To 
study the difference in engraftment of HESCs in the testis and the myocardium. 
 
Results 
In vivo histological analysis and immune response 
All SCID mice with testicular HESCs transplants developed teratoma two months after 
implantation. The cells in the teratoma were of human origin (Figure 19). When SCID 
mice were transplanted myocardially, only two of five mice developed teratoma-like 
tumors (Figure 20). C57BL/6 mice with testicular transplants and treated with 
costimulation blockade all developed teratoma surrounded by CD4+CD25+Foxp3+ 
regulatory T-cells, while isotype control treated recipients rejected their grafts. 
C57BL/6 mice transplanted intra-cardially and treated with costimulation blockade 
rejected their grafts within one month, demonstrated by lymphocyte infiltrates one 
month after transplantation (Figure 21). Repeated costimulation blockade three weeks 
after implantation of HESCs into the myocardium of C57BL/6 mice caused survival of 
HESC-derived cells after two months (n=1/5) (Figure 22). The surviving cells were in-
capsulated and there was no sign of inflammation. 
Mixed leukocyte reaction (MLR)  
MLR was designed to mimic the clinical setting of HESCs transplantation where the 
dendritic cells (DC) of the host present antigens from processed HESCs to host CD+ T-
cells. In figure 23, the CD4+CD25+ T-cells separated from the costimulation blockade 
group significantly down-regulated naive CD4+ T-cell proliferation with a mean of 
22% (P< 0.05), whereas CD4+CD25+ T-cells from the isotype control group did not 
inhibit proliferation of naive T-cells. Furthermore, the down-regulatory effect of the 
immune response mediated by CD4+CD25+ T-cells was specific to undifferentiated 
HESCs, since they did not inhibit the proliferation of naive T-cells stimulated by HFib.  
 
Conclusions  
Costimulation blockade is sufficiently robust to induce tolerance to undifferentiated 
HESCs in the immune-privileged environment of the testis and to induce regulatory T-
cells to HESCs when transplanted into the myocardium of immunocompetent mice. 
This peripheral tolerance seems to be mediated by HESCs specific regulatory T-cells. 
Figure 19. HESC-derived teratoma in the testis of a costimulation blockade treated 
C57BL/6 mouse 2 months after injection. The teratoma was of human origin; all cells 
were FISH positive (red cells) (left panel). CD4+CD25+Foxp3+ T-cells (green cells) 
were detected at the interface of normal tissue and teratoma in the testis (right panel). 
Bars represent 200 µm and 100 µm in left and right panels, respectively. 
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 Figure 20. Left panel: Hematoxylin and 
eosin staining of an expansive growing 
teratoma-like tumor in the heart of a SCID 
mouse  
Right panel: FISH staining reveals that the 
tumor originates from the HESCs (red 
cells). 
 
Figure 21. Immunological response to HESC transplanted into the myocardium 
of costimulation blockade treated C57BL/6 mice. Upper panel, this immune 
response was characterized by activated macrophages (CD11b+), T-cells (CD3+), 
where the T-cell response is characterized by both  CD4+ cells  and  CD8+ cells after 
1 month and in the lower panel, the same immune response was seen in one of the 
hearts (n= 1/6), 2 months after transplantation. In the majority of the hearts there was 
only a scar left in the myocardium two months after transplantation (n = 5/6). Bar 
represents: 100 µm in all panels apart from the lower right = 200µm.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 22. HESC 2 months after 
transplantation into the
myocardium of C57BL/6 mi
and received treatment with 
costimulation blockade directly 
after transplantation and then 
again 3 weeks later, which led to 
the acceptance of these cells in 
one recipient as demonstrated by 
the FISH positive  red cells. Bar 
re
 
ce 
Figure 23. MLR showed that regulatory T-
cells isolated from the costimulation 
blockade group down-modulated the 
immune response significantly, while 
regulatory T-cells isolated from the isotype 
control group did not. presents 200 µm. 
  
8 GENERAL DISCUSSION 
Cardiac regenerative cell-based therapy has emerged as a growing and promising future 
for therapeutic myocardial regeneration. Many challenges remain to be addressed 
before this approach can be applied in the clinic. One of the most important challenges 
is to elucidate which stem / progenitor cell is optimal for cardiac regeneration. By 
definition, the ideal cell population for cardiac cell-based therapy should be able to 
counteract the remodelling process that finally leads to heart failure. 
At the time that we started our project, the concept of heart-derived cardiac progenitor 
cells had emerged as a new field that circumvents most of the problems related to 
allogeneic pluripotent stem cells (Barile et al., 2007). Instead of evaluating different 
differentiation protocols for generation of cardiomyocytes from pluripotent and 
multipotent stem cells, we focused on identifying the optimal cell type that could meet 
the above-mentioned definition and could function as a template for future generation 
of cardiac progenitors (CPCs) from pluripotent stem cells like HESCs.  
Based on several previous reports that identified the LIM – homeodomain transcription 
factor Isl1 as a marker of multipotent undifferentiated cardiovascular progenitors 
residing in the heart (Cai et al., 2003; Sun et al., 2007), we have focused our research to 
characterize the Isl1 cardiac progenitors from the embryonic period to adulthood and 
how these cells respond to physiological and pathological stress. In this thesis a new 
concept of immunological tolerance to circumvent the immune rejection is presented. If 
clinical grade CPCs can be generated from HESCs appropriate cell quantities for 
cardiomyoplasty may be produced. 
 
  
8.1 THE JOURNEY OF ISL1 CELLS ALONG THE LIFE SPAN 
8.1.1 Spatial and time-dependent analysis of Isl1+ cells   
When we started this research, most of our understanding about the molecular and 
cellular basis of developmental cardiogenesis was based on studies of rodent hearts, 
mainly mice. In these studies presented here, we have compared the embryogenesis in 
humans with rats. Taken in consideration, the program that governs the cardiac 
development in humans, however, differs significantly from the murine program. 
Murine cardiogenesis takes places in about 48 hours; meanwhile human cardiogenesis 
occurs over weeks, so the extrapolation of data should be taken with caution. Another 
issue is the heterogeneity, logistics and scarcity of human embryonic material, 
explaining why no time-adjusted systematic characterization could be performed on 
this material. 
 
The role of the LIM homeodomain transcription factor Isl1 in the organogenesis of 
pancreas (Karlsson et al., 1990) and motor neurons of the ventral horn of the spinal 
cord has previously been well described (Tsuchida et al., 1994; Thor et al., 1999). 
Moreover previous studies have shown the importance of cardiac progenitors 
expressing Isl1 for the development of the embryonic heart (Cai et al., 2003; Yang et 
al., 2006; Sun et al., 2007). The genetic marking techniques used in these studies 
delineate specific cell types derived from Isl1+ cells, but they do not show the actual 
distribution of cells actively expressing the protein Isl1. In spite of that the 
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recombinase–based fate mapping technique is considered an important strategy for 
defining progenitor descendant relationships. However the interpretation of these data 
is a complex process which could explain the diverse results concerning the 
contribution of Isl1+ cells and their derivates to the first (FHF) and second heart fields 
(SHF) or both (Prall et al., 2007; Ma et al., 2008). To circumvent these problems in this 
thesis an Isl1+ cell is defined as a cell expressing the protein Isl1. 
 
In paper II, using a longitudinal rat study, we determined the distribution and level of 
differentiation of cells expressing the protein Isl1, from the embryonic period to 
adulthood (Genead et al., 2010a). Analysis was initiated at GD 11 in rats, which 
corresponds to GD 9 in mice at which time point growth retardation has been observed 
in Isl1 mutant mice (Cai et al., 2003). Isl1 expressing cells were identified along the 
entire life span from the embryonic period (GD 11-15), during which the majority of 
the cardiac morphogenesis takes place, until adulthood. During the early embryonic 
time period the Isl1+ cells were present in abundance in the para-cardiac tissue, 
including regions like pharyngeal foregut endoderm and splanchnic mesoderm, and to a 
lesser extent around the ventral and lateral aspects of the evolving trachea and the 
anterior cardinal veins. These areas are suggested to be the SHF and these findings 
support the idea that Isl1+ cells constitute the majority of the cells of the SHF (Cai et 
al., 2003; Buckingham et al., 2005). At GD 13 the Isl1+ cells were mainly found in the 
developing heart and less in the remnants of the SHF. This is consistent with the 
findings in mice where most of the Isl1 progenitors had migrated into the heart by GD 9 
(Sun et al., 2007). 
 
In paper II, the Isl1 protein expression differed with the age of the embryonic heart 
(Genead et al., 2010a). At the earlier stages of development, there was a smaller 
amount of Isl1+ cells present within the heart. These cells were mainly localized in the 
myocardial layer of the bulbotruncal region and truncus arteriosus and few scattered 
Isl1+ cells were also present in the common atrial chamber. At the later stages of 
development, more Isl1+ cells were observed in the proximal and distal outflow tract, 
at the junction between the OFT and the ventricles and to a lesser extent in the inflow 
part of the right atrium. No Isl1+ cells could be identified in the left ventricle (LV) at 
any developmental stage. These data are consistent with the previous reports based on 
retrospective clonal analysis and genetic fate-mapping studies in mouse embryos 
(Buckingham et al., 2005; Cai et al., 2003; Sun et al., 2007), which indicated that Isl1 
marks cells in the developing heart originating from the SHF. 
 
Few Isl1+ cells were also present in the postnatal rat heart, mainly as clusters in the 
OFT, and at the junction to the ventricular tissue. These results are in keeping with 
two reports. The first report by Laugwitz and coworkers, that described the presence 
of few Isl1 progenitors in the neonatal heart, mainly in the atria and the outflow tract of 
mouse, rat and human specimens (Laugwitz et al., 2005). In a second report by Amir 
and coworkers, human myocardial specimens obtained from the right ventricular 
outflow tract (RVOT) of children with congenital heart disease were studied (Amir et 
al., 2008). In these neonatal heart biopsies from infants not older than one postnatal 
week, very few Isl1+ cells were found, often no more than 1 to 2 cells per specimen. 
However, the interpretation of data should be taken with caution, because the samples 
were collected from neonatal hearts with congenital anomalies. Probably these Isl1 
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cells are developmental remnants of the embryonic progenitors since their distribution 
coincides with the cardiac structures known to evolving from the SHF.  
 
In continuum with the Isl1 cells journey along the entire life span, the presence of 
Isl1+ cells in the adult heart of pregnant rats was observed for the first time (Genead 
et al., 2010a). This is contradictory to previous reports where the Isl1 expression 
disappeared shortly after birth (Laugwitz et al., 2005). However, recently Khattar and 
his colleagues confirmed our findings, where they reported the presence of two 
subpopulations of Isl1 expressing cells in the young adult heart of different strains of 
mice (Khattar et al., 2011).  
In our study the Isl1+ cells were very few and scattered within the OFT. To keep in 
mind, these cells were observed in the hearts of pregnant rats, which raises the role of 
stress as a stimulus for up-regulating dormant endogenous cardiac progenitors. 
Another explanation might be that the adult heart contains a pool of cardiomyocytes 
that can change into a fetal phenotype including expression of Isl1 or re-enter the cell 
cycle upon stimulation. A recent report support the hypothesis that silent cardiac 
progenitors could be activated upon injury, during which Isl1-expressing 
cardiomyocytes could be detected throughout the ventricle of the adult newt hearts 
(Witman et al., 2011).  
 
The distribution of Isl1+ cells in aborted human embryonic hearts (gestational age 5-9 
weeks) was also studied, again looking at the protein expression (Genead et al., 2010b). 
In the human embryonic material, for the first time the distribution of Isl1+ cells was 
identified during the early first trimester (Genead et al., 2010b). This is the period 
during which major morphogenesis of the human heart takes place. The distribution of 
Isl1+ cells was in a time-dependent manner dynamically changing from clusters of 
Isl1+ cells, mainly located in the proximal and distal OFT at 5 weeks of gestation, to a 
wider distribution at 9 weeks, where the Isl1+ cells were present not only in the OFT 
but also in the right atrium, right ventricle and the interstitial septum. As in the rat 
model (Genead et al., 2010a), no Isl1+ cells were detected in the LV at any 
developmental time point. Even if the Isl1 distribution in humans has not been widely 
studied, there are few reports consistent with our data, Bu and co-workers reported that 
Isl1 cells were present in the right atria, outflow tract and the left atrial appendage in 
the late first and early second trimester (Bu et al., 2009). On the other hand, Amir and 
co-workers aimed to study the distribution of putative resident cardiac stem cells in 
neonatal human hearts, and used human embryonic hearts as controls (Amir et al., 
2008). In this study the Isl1 expressing cells in the embryonic hearts were found as 
clusters in the myocardial layer of the right atrial wall but nothing in the OFT or the 
ventricular tissues (Amir et al., 2008). In another study by Alfakir and coworkers 
looking at Isl1 mRNA expression, demonstrated Isl1 in RV, LV, RA, LA and OFT six 
weeks post conception (pc) meanwhile at 11 weeks pc the Isl1 mRNA was mainly 
expressed in the OFT and LA (Alfakir et al., 2010). Even if these reports describe the 
discrepancies in the distribution of Isl1+ cells in the human embryonic hearts reported 
in the different studies, Isl1+ cells are present and contribute to the development of the 
human embryonic heart in a similar manner as previously described for rodents 
(Genead et al., 2010a; Cai et al., 2003). Next it is important to characterize the 
differentiation and proliferative capacity of the in vivo expressing Isl1+ cells. 
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8.1.2 The differentiating and proliferative capacity of Isl1+ cells 
In paper I and II, the in vivo differentiation and proliferation profile expression of the 
Isl1+ cells were identified within the human and rat embryonic hearts. Only a few of 
the Isl1 expressing cells were in an undifferentiated stage, while the majority were in a 
differentiated stage, expressing smooth muscle and cardiomyocyte markers (Genead et 
al., 2010a; Genead et al., 2010b). Several reports in mouse and human support these 
findings, describing a down-regulation of the Isl1 expression after migration into the 
heart when the Isl1+ cells start to differentiate and contribute to the constituents of 
the heart i.e. cardiac myocytes, smooth muscle and endothelial cells during heart 
development (Cai et al., 2003; Sun et al., 2007; Bu et al., 2009). Furthermore, in 
studies by Kruithof and coworkers, they revealed that the OFT myocardium consists 
of relatively undifferentiated CPCs (Kruithof et al., 2003). This balance between the 
fully differentiated and undifferentiated cell population may be crucial during heart 
development, leaving an endogenous reservoir of cells with high plasticity. 
 
Unexpectedly both in rat and human embryonic hearts only few of the Isl1+ were 
showing signs of cell cycle activity (Genead et al., 2010a; Genead et al., 2010b). 
Instead, in the embryonic heart, the cells that demonstrated the highest proliferative 
capacity were the cardiomyocytes (Genead et al., 2010a). According to the results by 
Cai et al, in mice the Isl1 expression was down-regulated as soon as the Isl1+ cells 
started to differentiate into cardiomyocytes (Cai et al., 2003). In contrast, in our 
embryonic rat study, Isl1 protein was expressed together with cardiomyocyte and 
smooth muscle markers (Genead et al., 2010a). In the postnatal period, there were 
still undifferentiated Isl1+ cells in the OFT, some of them were proliferating and 
others also expressing the mature cardiomyocyte (TnT) marker. Even in the adult 
heart we could identify a few Isl1+ cells, all of which had also expressed 
cardiomyocyte marker TnT. No undifferentiated Isl1+ cells were present in the adult 
heart.  
 
To discuss further the issue of in vivo dynamics of proliferation in both the embryonic 
and the postnatal heart, several aspects should be highlighted.  
First as regards the pattern of cell proliferation in the embryonic period, there is an 
initial period of rapid cell proliferation at about E8 in mouse (Pasumarthi and Field, 
2002; Alsan and Schultheiss, 2002) then a transiently slower phase of proliferation, 
and finally a second peak of proliferation at E11 (Pasumarthi and Field, 2002). 
However, the molecular mechanisms regulating these waves of proliferation within the 
cardiac mesoderm are poorly understood, concerning which cells (the progenitor pool 
or the embryonic cardiomyocytes) are responsible for proliferation.  
In paper I, the majority of the ventricular cardiomyocytes expressed the cell-cycle 
associated nuclear protein, Ki67, while unexpectedly only a few Isl1+ cells co-
expressed the same marker in their areas of preferred distribution, namely the outflows 
tract (Genead et al., 2010a). This is consistent with findings observed during the 
embryonic heart development, where different cardiac subdomains demonstrated 
different proliferation patterns. Increased levels of cell proliferation were observed in 
the myocardium of the atria and ventricles, in comparison to the OFT (Christoffels et 
al., 2000). 
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A recent report by Walsh and co-workers, combining FACS sorting and 
immunostaining for BrdU uptake or Ki-67 indicated that a range of 12–23% 
(depending on different methods) of embryonic cardiomyocytes were positive for cell-
cycle markers. This activity declined rapidly in the postnatal period (Walsh et al., 
2010). In paper II, two markers instead of one were used to evaluate the proliferative 
capacity of the studied cardiac cells. A rather wide range of difference in the percentage 
of the positive cells expressing the two markers (Ki67 or phosphorylated H3) were 
observed, consistent with data obtained from Walsh and co-workers. 
Several reports support the possibility that fully differentiated cardiomyocytes within 
the developing myocardium continue to proliferate, co-expressing phospho-histone 
H3, indicating that even fully differentiated cells have a dividing capacity as they 
undergo full differentiation (Goetz et al., 2006; Pasumarthi and Field, 2002). The same 
applies for many other tissues such as the skeletal muscle and the nervous system, in 
which cell cycle withdrawal is tightly associated with the onset of terminal 
differentiation (Alexiades and Cepko, 1996; Walsh and Perlman, 1997).  
 
In our model we reported only few Isl1+ progenitor cells within the embryonic heart 
co-expressing markers of cell proliferation. Consistent with these observations, a report 
by Amir and colleagues demonstrated several populations of CPCs in the human fetal 
and early infant myocardium and evaluated their rate of proliferation (Amir et al., 
2008). They showed that the majority of differentiated cardiomyocyte co-expressed 
Ki67 during the fetal period (40-70%), declining rapidly in the postnatal period. In 
contrast, only few c-Kit progenitors and early cardiomyocyte progenitors expressing 
NKx2.5  expressed the Ki67 in the fetal heart, which further decreased after birth (Amir 
et al., 2008). Taken altogether, the unexpected findings of few Isl1+ cells expressing 
Ki67 were consistent with reported findings that only few c-Kit+ cells expressed Ki67 
in the fetal and early postnatal period (Amir et al., 2008). 
 
Another methodological aspect should be considered regarding the use of Ki67, which 
is considered as a marker of cell-cycle activity, indicating that the cells are not in the 
G0 phase of cell cycle. However this does not mean that they undergo active cellular 
division (cytokinesis). Several reports based on Ki67 positive cardiomyocytes might 
reflect a nuclear division (karyokinesis) without concurrent cytoplasmic division 
(Beltrami et al., 2001; Meckert et al., 2005).    
In our model we analysed cellular proliferation using Ki67 on in situ sections at a 
certain time point, which is not the optimal. This means that it was difficult to trace the 
proliferative pattern of our cells of interest i.e. the Isl1 in a real-life imaging. However, 
the in vitro model from the embryonic heart material revealed a rather modest degree of 
proliferation, which was similar to our in vivo results (data not shown). 
To label the isolated Isl1 cells in-vivo and trying to trace them under different 
conditions would be of great importance to study their dynamics. Another aspect would 
be to isolate the Isl1 cells from the tissue and study them in vitro. This is under 
investigation in our laboratory. 
 
From the above discussions concerning the Isl1 journey, it is hypothesized that during 
cardiogenesis, the pool of Isl1+ cells, while migrating into the developing heart from 
their extra-cardiac regions, undergoes an active conversion from a multipotent stage 
to a more lineage restricted stage. At the same time, the Isl1 expression is down-
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regulated due to differentiation into cardiomyocytes, and their proliferative capacity 
is turned down (Figure 24).   
 
Figure 24. Schematic illustration showing the mammalian embryonic heart 
development and the proposed role of the Isl1 progenitors.  
FHF: first heart field; SHF: second heart field; CNC: cardiac neural crest; CT: 
conotruncal; AS: aortic sac; RV: right ventricle; LV: left ventricle; RA: right atrium; 
LA: left atrium; Ao: Aorta; PA: pulmonary artery; V: Common ventricle; A: common 
atria. 
 
In order to study the in vitro proliferating and differentiating capacity of embryonic 
cardiomyocytes cultures from human embryonic hearts were generated (Genead et al., 
2010b). In culture the embryonic cardiomyocytes developed into spontaneously beating 
cardiospheres (CSs). The CSs contained a heterogeneous population of cardiomyocytes 
at different level of differentiation. The majority of the cells expressed cardiomyocyte 
markers like TnT, representing more mature cells. The CSs also contained a mixture of 
early cardiomyocyte progenitors expressing Nkx2.5 but there were only a few Isl1+ 
cells present. In electron microscopy the cells contained contractile elements, 
mitochondria and formed gap junctions with the surrounding cardiomyocytes. The CSs 
also responded to external stimuli like electrical stimulation and β-adrenergic 
stimulation by reducing the field potential duration and decreasing the inter-beat 
interval, thus beating with a higher frequency. Consistent with these data, other studies 
have reported CSs that were obtained from rodents, pigs and human biopsy of adult 
hearts. These CSs demonstrated a similar heterogeneity of cells (Messina et al., 2004; 
Miyamoto et al., 2010; Smith et al., 2007). 
The generation of 3D CSs for implantation purposes represents a potential promising 
strategy for cardiomyoplasty. The 3D structure closely resembles the “niche” in terms 
of interaction among different cells and their supporting matrix, which should improve 
survival of the cells after implantation. Recent studies in mouse and pigs, revealed 
greater benefits of 3D cardiospheres in comparison to the regular 2D structures when 
transplanted into an ischemic model (Lee et al., 2011; Li et al., 2010). Therefore it was 
important to show that the generated human CSs responded to external stimuli, 
otherwise there should be a risk of arrhythmia after implantation.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Moreover our results can provide the basis for development of an in vitro system with 
beating cardiomyocytes for evaluating the cardiotoxicity of different drugs, thus 
preventing the development congenital malformations (Danielsson, 2010).   
The CSs used in our study were derived directly from the culturing of early 
embryonic cardiomyocytes and cardiac progenitors (Genead et al., 2010b). The 
optimal situation would be if it was possible to isolate the Isl1+ progenitors, expand 
them in vitro and then differentiate them into spontaneously beating cardiospheres.  A 
recent study that supports this idea has employed fluorescence-marked transgenic 
embryo and embryonic stem cells as well as combinations of positive and negative 
fluorescence activated cell sorting to document the presence of FHF and SHF 
progenitors with distinctive transcriptional profiles (Domian et al., 2009). They showed 
that the transcriptional Isl1 / Nkx2.5 signature gave rise to a spontaneously beating 
three dimensional muscular film.   
An option would be to determine a specific profile of surface markers expressions of 
Isl1+ cells of the human embryonic heart. Then a similar strategy might be used for 
generating beating cardiomyocytes for cardiomyoplasty. Another strategy would be to 
generate Isl1+ cells from HESCs and implant them using tolerance induction to prevent 
immune rejection. Since Isl1+ cells seem to be present even in the adult heart, it might 
even be possible to stimulate the endogenous regenerative capacity and thereby inhibit 
the remodelling process that follows heart failure development.  
 
 
8.2  CPCs TURNOVER IN RESPONSE TO STRESS  
Paper II is the first report on the detection of scattered Isl1+ cells within the outflow 
tract of adult pregnant rat heart (Genead et al., 2010a). The hypothesis was that 
pregnancy, as a kind of physiological stress, plays a role in altering the dynamics and 
turnover of cells within the adult heart. In accordance with this hypothesis, an 
experimental design was set up to explore how cardiac regeneration and cell turnover 
adapted to various stress modalities like pregnancy, myocardial infarction and 
ischemia-reperfusion with or without the growth factors IGF-1 and HGF (Genead et al., 
2011).  
 
Previous reports have revealed that the adult heart is a highly dynamic organ in which 
cardiac homeostasis can be modulated under various physiological or pathological 
states (Kajstura et al., 2010; Nadal-Ginard et al., 2003). Our study systematically 
examined for the first time the time-dependent and spatial up-regulation of the best 
characterized cardiomyocyte progenitor markers c-kit and Isl1, as well as the early 
cardiomyocyte marker Nkx2.5, during experimental pathological and physiological 
stress stimuli in adult rat heart (Genead et al., 2011). Observations were based on 
mRNA and protein analysis of tissue specimens from the different cardiac sub-
domains. In this way, the expressions of Isl1, c-Kit and Nkx2.5 were verified by two 
independent methods. 
In order to compare the up-regulation of our target marker Isl1, we chose another well 
studied progenitor marker namely c-Kit. This is the tyrosine kinase receptor for the 
stem cell factor (SCF) and was initially reported as a hematopoietic stem cell marker, 
with controversial data regarding their cardiomyogenic in vivo potential (Lyman and 
Jacobsen, 1998). c-Kit+ cells as resident progenitors in the heart were first reported in 
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2003 (Beltrami et al., 2003). Beltrami and co-workers succeeded to isolate c-Kit+ /Lin-
/CD45- from rats and demonstrated their potential for myocardial regeneration by 
differentiating them into all the cardiac lineages and regenerating infarcted 
myocardium. Furthermore, c-Kit+ cells have also been isolated from human hearts, and 
upon transplantation into infarcted myocardium of immunodeficient rats, they 
generated a chimeric heart, with new population of cardiomyocytes and vasculature 
(Bearzi et al., 2007; Beltrami et al., 2003). Another advantage of using these cells for 
cardiomyoplasty is that in culture c-Kit+ cells exhibit long term stability, self renewal 
and clonogenic properties (Miyamoto et al., 2010). However, the origin and phenotype 
of the c-kit+ cells in the adult heart is still under debate. All c-Kit+ cells are not stem 
cells since c-Kit can also be expressed on mast cells or other hematopoietic cells 
(Baghestanian et al., 1997; Pouly et al., 2008; Sandstedt et al., 2010; Zhou et al., 2010). 
 
Among the different stimuli, ischemia-reperfusion injury induced the strongest up-
regulation of both c-Kit and Nkx2.5. This up-regulation was time-dependent and was 
detected throughout the entire heart. The up-regulation of c-Kit could not solely be 
explained by activation of mast cells in the heart, since the c-Kit expression did not 
correlate to the changes of mast cells expression.  
Whether the stem / progenitor cells in general, represent different subpopulations or 
whether they derive from a common precursor have not been resolved. In paper III, 
there was a spatial mismatch on one hand of c-Kit and Nkx2.5 and on the other Isl1 
expression, indicating their different dynamics and origins. Both c-Kit and Nkx2.5 
were globally up-regulated, while Isl1 up-regulation was localized to the outflow 
tract, where these cells previously have been demonstrated to reside in the rat and 
human embryonic hearts (Genead et al., 2010a; Genead et al., 2010b).  
Consistent with these findings, several reports have revealed the existence of two 
different subpopulations of cells expressing c-kit and Isl1 (Pouly et al., 2008; 
Laugwitz et al., 2005). Moreover, Itzhaki-Alfia and co-workers isolated viable heart 
cells, from patients during heart surgery or as endomyocardial biopsies. These cells 
expressed both c-Kit and Isl1 and the best source was from the right atrium of 
females. In vitro, no overlap was observed between these two markers, indicating the 
existence of two subpopulations and the possible role of stress in altering the dynamic 
expression of markers (Itzhaki-Alfia et al., 2009).  
 
In paper III, interestingly, ischemia-reperfusion (IR) injury was the strongest stimulus 
for the up-regulation of both c-Kit and Isl1. In contrast to c-Kit, Isl1 was not up-
regulated by pregnancy or myocardial infarction. Consistent with these data Hsieh and 
co-workers, based on a genetic fate-mapping study, revealed that there was an 
increased turn-over of cardiomyocytes in adult mice with ischemia and pressure 
overload (Hsieh et al., 2007). Which progenitor cell markers were associated to this 
endogenous turn-over of cardiomyocytes were not studied. Kubo and co-workers 
reported an increasing abundance of c-Kit cardiac progenitors in patients with advanced 
heart failure regardless of the underlying etiology (Kubo et al., 2008). These 
observations may suggest that some factors are released during these pathological states 
that induce the up-regulation of cardiac progenitors stimulating the regeneration of new 
cardiomyocytes. Alternatively, the stress on the heart may induce a fetal cardiomyocyte 
phenotype with up-regulation of markers such as Nkx2.5, c-Kit and Isl1.  
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It was interesting to study if the endogenous IGF-1 and HGF are involved in the up-
regulation of cardiac progenitor markers in the IR model and if exogenous local 
administration of these growth factors could further potentiate this effect. Based on 
previous studies, the role of these growth factors as cytoprotective, angiogenic and anti-
apoptotic effects have been established (Torella et al., 2004; Wang et al., 2004). We 
concluded that the endogenous up-regulation of IGF-1 and HGF followed the same 
pattern as for the studied cardiac progenitor markers. The addition of IGF-1 and HGF 
could further boost the endogenous expression of these growth factors which 
subsequently further stimulated the expression of Isl1, especially in the outflow tract, 
but did not further affect the expression of c-Kit. A recent study by Ellison and co-
workers revealed that the intracoronary injection of IGF-1/HGF activated the 
endogenous cardiac stem cell pool and improved the cardiomyocyte survival in a pig 
model (Ellison et al., 2011). Similar effect applies when CPCs were injected together 
with IGF-1 bound to self-assembling peptide nanofibers in the infarction border zone, 
which stimulated cardiomyogenesis (Padin-Iruegas et al., 2009).  
 
This concept actually opens up a new field. It might be possible to stimulate and 
thereby augment the endogenous regenerative capacity of the heart. This offers distinct 
advantages to stem cell implantation since the problems with engraftment and immune 
rejection are avoided.  
 
 
8.3 IS IT POSSIBLE TO INDUCE IMMUNE TOLERANCE TOWARDS 
HESCs? 
Cardiac regenerative medicine is a potential alternative to conventional therapies. 
However several challenges need to be overcome, one being the prevention of 
immunological rejection. In this thesis, focus has been on cardiac progenitors as 
potential cell source for myocardial regeneration. A potential source for large 
amounts of progenitor cells is embryonic stem cells. In order to test the 
immunological aspect of cell transplantation of such cells and due to a lack of a 
sufficiently pure population of Isl1 progenitors, undifferentiated HESCs were chosen 
for the study of immune tolerance. 
 
In the clinical setting, despite the great potential of HESCs, several challenges 
concerning their immunogenicity have not been fully addressed and strategies to 
avoid rejection remain largely unsolved. Conflicting data exist concerning whether 
the HESCs are immune privileged or not. Early reports indicated that HESCs could 
be immune privileged (Drukker et al., 2002; Li et al., 2004), because they do not 
express HLA class II molecules and show limited expression of HLA class I 
molecules. However, recent studies showed that HESCs can induce immune rejection 
in xenogeneic transplantation (Grinnemo et al., 2006; Swijnenburg et al., 2008). Thus 
to overcome the immunogenicity of transplanted HESCs, an immunomodulatory 
regimen is necessary. Preferably the ideal immunosuppressive therapy should involve 
only a brief period of immunosuppression but be able to induce specific and long-
term tolerance to the donor cells with limited side-effects (Chidgey et al., 2008). 
The strategy of blocking costimulatory molecules at the time of transplantation has 
emerged as a promising strategy. This can be achieved by treating the recipient with 
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monoclonal antibodies and receptor specific fusion proteins the first week after 
transplantation. The most well characterized are the B7-CD28 family (Greenwald et 
al., 2005; Sharpe and Freeman, 2002), CD40-CD40L (TNF receptor family) (Croft, 
2003) and LFA-1 (Van Seventer et al., 1990; Zuckerman et al., 1998). The combined 
use of anti-CD40ligand (CD40L) and cytotoxic-T-lymphocyte-associated antigen 4 
(CTLA4Ig), which blocks B7 signaling, showed synergistic effects on the induction 
of transplantation tolerance in rodents and nonhuman primates (Larsen et al., 1996; 
Kirk et al., 1997). LFA-1 is essential to the formation of the immunological synapse 
as well as the trafficking and costimulation of T-cells. By adding anti-LFA-1 to anti-
CD40L and CTLA4Ig synergistic effects are achieved (Larsson et al., 2003). 
 
In paper IV, this triple costimulation blockade regimen (CTLA4Ig/ anti-CD40L/ anti-
LFA-1) was tested in a mouse model, to evaluate the potentiality to induce immune 
tolerance to transplanted HESCs (Grinnemo et al., 2008). The costimulation blockade 
was sufficiently robust to induce tolerance to undifferentiated HESCs in the immune-
privileged environment of the testis (Nasr et al., 2005) and to induce regulatory T-
cells to HESCs when transplanted into the myocardium of immunocomptent mice. 
These results are in keeping with the ability of the costimulation blockade to induce 
tolerance to cardiac allografts (Larsen et al., 1996), pancreatic islets (Lenschow et al., 
1992; Kumagai-Braesch et al., 2007), and bone marrow transplants (Kurtz et al., 
2009). 
 
In paper IV, in contrast to HESCs transplanted to the testis, no surviving cells could 
be seen when transplanted into the myocardium of costimulation blockade treated 
mice. When treated with a booster dose of the costimulation blockade, HESC-derived 
cells with a teratoma-like structure were found in only one out of five mice. 
Transplanted HESCs induce an acute CD4+ T-cell mediated rejection which is 
inhibited by the blockade of costimulatory molecules. This leads to a state of non-
reactivity in the helper T-cell population which leads to the generation of 
immunological memory. This memory is maintained by regulatory T-cells 
(CD4+/CD25+/Foxp3+) specific to the undifferentiated HESCs. These regulatory T-
cells then inhibit new naive T-cells which are potentially reactive towards HESC and 
thereby prevent rejection in the future. 
 
Immunological self-tolerance can be either central (thymic) tolerance or peripheral 
(non-thymic) tolerance. Peripheral tolerance is a consequence of inappropriate 
costimulation of T-cells after having exited the thymus resulting in T-cell anergy or 
non-reactivity. Some of these anergic T-cells differentiate into regulatory T-cells 
(Miyara and Sakaguchi, 2007). Regulatory T-cells have been linked to the induction 
of transplantation tolerance in preclinical studies (Joffre et al., 2008) and to stable 
renal-allograft function (Kawai et al., 2008). 
In paper IV, the existence of the regulatory T-cells in the testis support the hypothesis 
that costimulation blockade induced peripheral tolerance similar to other studies using 
the same protocol (Kumagai-Braesch et al., 2007). The isolated regulatory T-cells 
from the costimulation blockade group down-regulated the immune response induced 
by HESCs in vitro. This effect was specific to HESCs and not human fibroblasts, 
indicating that the recipient became immunologically tolerated towards the 
undifferentiated HESCs. 
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A recent study by Pearl and co-workers showed that blocking leukocyte 
costimulatory molecules permit ESC engraftment. They have demonstrated the 
success of this immunosuppressive therapy for undifferentiated mouse and human 
ESCs, iPS as well as more differentiated ESCs derivatives. In addition, they showed 
that the tolerance induced by the costimulation blockade is antigen-specific consistent 
with our findings described above (Pearl et al., 2011). 
 
These findings are promising but still many challenges and questions need to be 
clarified before proceeding to the clinic. Attempts to use anti-CD40L in a clinical 
setting were unsuccessful because of thromboembolic events complicating their 
administration (Sidiropoulos and Boumpas, 2004). As an alternative to overcome this 
problem, humanized mouse antihuman CD40Ab has been developed and tested in 
nonhuman primates and demonstrated allograft survival (Haanstra et al., 2003). 
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9 CONCLUSIONS 
 
 The human embryonic heart can be a potential source of cardiac progenitor 
cells. 
 
 Clusters of Isl1+ cells are present in the early first trimester human embryonic 
heart. Some Isl1+ clusters are undifferentiated while others express 
cardiomyocyte and smooth muscle lineage markers. Spontaneously beating 
cardiospheres from the human embryonic heart responded to electrical and 
pharmacological β-adrenergic stimulation. This is an important characteristic if 
these cells are to be used clinically. 
 
 During embryogenesis in a longitudinal rat model, Isl1 cells seem to migrate 
from extra-cardiac regions into the proximal part of the heart, proliferating and 
giving rise to cardioblasts. Part of the Isl1+ cell pool persists into adulthood. 
 
 Ischemia-reperfusion injury among other stress modalities was the strongest 
stimulus for up-regulation of cardiac progenitor cell markers suggesting 
activation of an endogenous cardiomyocyte regenerative reserve, correlating to 
up-regulation of endogenous IGF-1 and HGF. There was correlation between 
the up-regulation of the both progenitor cell markers Isl1 and c-Kit and the up-
regulation of the early cardiomyocyte marker Nkx2.5. 
 
 A short course of costimulation blockade induced long-term tolerance to 
undifferentiated HESCs in the immune-privileged environment of the testis and 
induced regulatory T-cells specific to the undifferentiated HESCs when 
transplanted into the myocardium of immunocompetent mice. A booster dose of 
costimulation blockade enhanced xenograft graft survival in the myocardium. 
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10 FUTURE PERSPECTIVES 
 
 The existence of the Isl1+ cells was demonstrated in the human 
embryonic heart. So it is worthy to consider the human embryonic 
material as a potential source for cardiac progenitors from which a 
relatively homogenous population of the Isl1 CPCs could be expanded 
in vitro for future use in cardiomyoplasty. 
 
 The ability to develop the cardiospheres from human embryonic hearts 
could open new windows for using these promising 3D structures in 
transplantation studies and evaluate their role in improving cardiac 
functions. 
   
 Isl1 cardiac progenitors are considered as promising endogenous cardiac 
progenitors. In order to get a pure population of thee Isl1+ cells isolation 
is mandatory. However, this is not applicable at this moment because 
Isl1 is a nuclear transcription factor. Isolation is usually based on the 
expression of surface markers so one possibility would be to identify a 
cell surface marker profile that specifically identifies Isl1 cells. As part 
of such a strategy, these cells need to be further characterized both at the 
transcriptional and protein levels. In the next step it might be possible to 
expand and subsequently differentiate the Isl1 population ex vivo for 
future use in clinical trials.  
 
 The concept of myocardial regeneration by means of stimulating or 
augmenting the endogenous regenerative potential is an attractive 
approach and more easily applicable in the clinic than the administration 
of stem cells. In paper III, our preliminary results could demonstrate the 
up-regulation of the studied cardiac progenitor markers as a response to 
different kinds of stress. Exogenous administration of growth factors 
potentiated these up-regulations. Several options are warranted to be 
tested in order to elucidate the mechanistic background and underlying 
mediators of such a regenerative response. In the next step these growth 
factors could be utilized to boost the endogenous regenerative capacity 
seen in patients with ischemic heart failure and thereby circumvent the 
need for stem cell transplantation. Another aim is to evaluate the 
effectiveness of the paracrine response induced by different stem cells, 
like mesenchymal stem cells.  
 
 The promising results concerning the immune tolerance induced by 
short term use of costimulation blockade could open a new window to 
test this regime in transplantation studies on other cell types like Isl1+ 
cells. 
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